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ABSTRACT 
 
 
 The chemical modification of proteins has been a longstanding interest in the 
scientific community. In addition to the natural modifications necessary for life to 
function, unnatural covalent modifications are particularly useful because they facilitate 
research efforts that require the precise manipulation of protein, including the 
installation of fluorescent labels, post-translational modification mimics, and affinity 
reagents. Historically, appending such modifications onto proteins was achieved by 
generating covalent adducts onto one of the twenty canonical amino acids. However, 
such modifications are not site-selective, and may interfere with the native function of 
the modified protein. 
 Genetic code expansion can overcome the limitations inherent to canonical amino 
acid modification, especially when bioorthogonal functional groups are incorporated. 
Using orthogonal aminoacyl-tRNA synthetase-tRNA pairs, one can reliably obtain 
homogenous samples of modified protein in a site-selective manner. In order to fully 
understand the steric requirements of a rationally designed pyrrolysyl-tRNA synthetase, 
several large meta-substituted phenylalanine derivatives were synthesized and 
incorporated into superfolder green fluorescent protein using this synthetase. All 
synthesized substrates were incorporated, albeit with differing incorporation efficiencies. 
Moreover, this synthetase was found to incorporate 3-formyl-phenylalanine, an 
aldehyde-based amino acid that can be directly installed onto proteins. Prior to this work, 
  iii 
only indirect post-translational approaches could install aldehydes, and these 
methodologies were limited as to where the modification could occur. Aldehyde labeling 
occurs rapidly at neutral pH, and peptide cyclization has been accomplished using the 
aldehyde to form a thiazolidine linkage with an N-terminal cysteine, further 
demonstrating the rich chemistry available to aldehydes. Finally, efforts to optimize 
azidophenylalanine bioconjugation led to a kinetic investigation of copper-catalyzed 
click chemistry, which led to a revision of the currently accepted mechanism; it is 
proposed that copper-catalyzed click chemistry requires two separate copper-chelating 
events, with one equivalent of copper binding to azide, and another equivalent of copper 
binding to alkyne. The work presented herein demonstrates that phenylalanine 
derivatives are useful substrates for probing and manipulating biological systems, as 
well as providing opportunities for discovery in chemical biology. 
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NOMENCLATURE 
 
AIBN    Azobisisobutyrylnitrile 
Amp    Ampicillin 
AzF    Azidophenylalanine 
AzFRS   Azidophenylalanyl-tRNA synthetase 
BTTAA                                  bis[(tert-butyltriazoyl)methyl]-[(2- 
                                               carboxymethyltriazoyl)methyl]-amine  
BTTP                                     3-[4-({bis[(1-tert-butyl-1H-1,2,3-triazol-4- 
                                               yl)methyl]amino}methyl)-1H-1,2,3-triazol-1-yl]propanol 
CAT    Chloramphenicol acyltransferase 
cfu    Colony forming unit 
Cm    Chloramphenicol 
CuAAC   Copper-catalyzed azide-alkyne cycloaddition 
CV    Column volume 
DBCO                                     Dibenzocyclooctyne 
DCM    Dichloromethane 
DEAD    Diethyl azodicarboxylate 
DIBAL-H   Diisobutylaluminum hydride 
DMAP    4-Dimethylaminopyridine 
DMF    Dimethylformamide 
DMSO    Dimethyl sulfoxide 
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DNA    Deoxyribonucleic acid 
EDC    1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EPL    Expressed protein ligation 
ESI-MS   Electrospray ionization-mass spectrometry 
EtOAc    Ethyl acetate 
FRET    Förster resonance energy transfer 
Hex    Hexanes 
IPTG    Isopropyl β-D-1-thiogalactopyranoside 
Kan    Kanamycin 
MeCN    Acetonitrile 
MjTyrRS   Methanococcus jannaschii tyrosyl-tRNA synthetase 
mRNA    Messenger ribonucleic acid 
NBS    N-bromosuccinimide 
NCAA    Non-canonical amino acid 
NCL    Native chemical ligation 
NMR    Nuclear magnetic resonance 
O.D.    Optical density 
OmpX    Outer membrane protein X 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PEG    Polyethylene glycol 
PheRS    Phenylalanyl-tRNA synthetase 
  ix 
ProY    Propargyl-tyrosine 
PTM    Post-translational modification 
Pyl    Pyrrolysine 
PylRS    Pyrrolysyl-tRNA synthetase 
r.p.m.    Rotations per minute 
RNA    Ribonucleic acid 
SDS-PAGE   Sodium dodecylsulfate polyacrylamide gel electrophoresis 
sfGFP    Superfolder green fluorescent protein 
SPPS    Solid phase peptide synthesis 
TEV    Tobacco etch virus 
THF    Tetrahydrofuran 
tRNA    Transfer ribonucleic acid 
tRNAPyl/CUA   Pyrrolysine tRNA (anticodon: CUA) 
tRNATyr/CUA   Tyrosine tRNA (anticodon: CUA) 
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1. INTRODUCTION  
1.1. Protein Biosynthesis and Post-Translational Modifications 
The twenty canonical amino acids are a universal necessity for life to function 1. 
Through the judicious and practically inerrant translation of the genetic code, organisms 
synthesize a wide variety of proteins and enzymes, biomolecules essential for catalyzing 
biochemical processes or for providing essential structural motifs in the organism. Each 
amino acid possesses a unique functional group substituted at the β-position relative to 
the carboxylic acid, and the summation of these functional groups in a polypeptide 
dictate the specific three-dimensional structure and properties of a protein.  
The central dogma of biology outlines the general method of information transfer 
(Figure 1.1);2 DNA is transcribed into messenger RNA (mRNA), which is finally 
translated into proteins. To put succinctly, during the translation process, elongation 
factors deliver aminoacylated transfer RNA (tRNA) to the A site of the ribosome, a 
biomolecule responsible for coupling amino acids to the growing polypeptide chain. 
Upon addition of this amino acid via peptidyltransferase activity, the ribosome is moved 
toward the 3’ end of mRNA, moving one codon length (three nucleotides) at a time in 
the process, ejecting uncharged tRNA from the E site of the ribosome and making the A 
site vacant for the next aminoacylated tRNA. Translation continues until the ribosome 
encounters a stop codon, one of three unique nucleotide sequences (UAG, UAA, and 
UGA) that recruit release factors, polypeptides that mimic the three-dimensional 
structure of tRNA and trigger disassembly of the translational machinery. 
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After translation, proteins may require further processing to become fully 
functional; amino acid residues are often chemically modified to alter their properties.3 
These post-translational modifications (PTMs) are capable of adding or attenuating 
charges (i.e. acetylation, methylation, phosphorylation),3,4 modulating transcription 
factor activities (glycosylation),5-7 and/or appending signals for protein trafficking and 
degradation (e.g. ubiquitination).8,9 The summation of various PTMs alter the form and 
UCA
GCC AGU
aminoacyl-tRNA synthetase
5'
UCA
5'
UCA
5'
CGG
5'
5' 3'
A SiteP Site
3'
1
2
3
Elongation
Factors
Figure 1.1. Protein translation.  (1) tRNA is aminoacylated by aminoacyl-tRNA 
synthetase, followed by (2) elongation factor-mediated transport into the 
ribosome (in pink) and (3) elongation of the nascent peptide chain via 
peptidyltransferase activity of the ribosome. 
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function of proteins by modulating their affinity for other biomolecules as well as 
providing localized perturbations that can alter the secondary structure of said protein. A 
survey of common post-translational modifications is provided in Figure 1.2. 
 
 
 
 
 
 
 The existence of post-translational modifications verify that “default” amino acid 
residues are not all that is required for life to function, and that small changes can have a 
profound influence on the overall form and function of a protein. Unnatural chemical 
modification of proteins can serve a variety of purposes, including the installation of 
PTM mimics, spectroscopic probes, and affinity tags. Initially, investigators that sought 
to chemically modify proteins were limited to modification onto one of the twenty 
canonical amino acids.10-14 Of these, the two most commonly employed substrates were 
cysteine and lysine. Cysteine has been a useful handle for protein modification because 
NH2
OH
O
H
N
O NH2
OH
O
N
NH2
OH
O
O
P
O
O
O NH2
OH
O
O
P
O
O O
NH2
OH
O
N
H
N
NH
NH2
OH
O
O
O
NHAc
HO
HO
OH
Figure 1.2. Selected examples of post-translational modifications found in nature. 
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it is relatively rare and is highly nucleophilic, thus providing opportunities for selective 
modifications. Proteins have been successfully modified at cysteine residues using a 
number of electrophiles, including disulfides, iodoacetamides, and Michael acceptors. 
Lysine has also been utilized for bioconjugation purposes, and although this amino acid 
is far more abundant compared to cysteine, the number of methods available for 
chemoselective primary amine modification has led to the modification of lysine in 
numerous methodologies. Activated esters, sulfonyl chlorides, isocyanates, and 
isothiocyanates have all been useful electrophiles for lysine modification. 
 
 
 
HS
NH3
R
S
NH
Residue
Cys
Cys
Cys
Lys
Lys
Lys
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S S
R'
Reagent Electrophile (R)
N
H
O
I
N
O
O
Residue Reagent Electrophile (R)
O
N
O
O
O
SCl
O
O
NCO
NCS
Figure 1.3. Bioconjugation methods using cysteine and lysine. Figure adapted from Sletten and Bertozzi. 
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 While the above methodology has utility under the appropriate context, 
modification of native amino acids has several drawbacks. For example, modification is 
usually not site-selective, unless one can ensure that only one residue of the amino acid 
is present in the protein. Secondly, the modified residues may be essential for the protein 
to function properly. Lastly, their utility as handles for in vivo experiments is diminished 
because of the organism-wide presence of cysteine, lysine, and biomolecules with 
similar functionality. 
1.2. Bioorthogonal Chemistry 
 In order to circumvent the limitations imposed upon canonical amino acid 
bioconjugation, it is necessary to utilize chemoselective reactions that do not interfere 
with functional groups found in organisms. Such reactions are said to be 
“bioorthogonal”,14 and several notable examples have been developed and utilized for 
various applications. All reported bioorthogonal reactions have been simple, second-
order reactions that can react relatively quickly and selectively under biological settings. 
As discussed later in this Chapter, bioorthogonal reagents can be installed using a 
number of different methods, including incorporation as non-canonical amino acids. The 
most common bioorthogonal reactions are discussed in detail below (Figure 1.4). 
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with nitrones
Copper (I) required, but
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in situ.  Unstrained olefins
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Figure 1.4. Survey of common bioorthogonal reactions. 
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1.2.1. Carbonyl-Based Methods 
 The earliest known example of a bioorthogonal reaction is the utilization of 
aldehydes and ketones for condensation with hydrazines or hydroxylamines, and this 
reaction continues to be a useful bioconjugation tool15-17 (Figure 1.4, entry 1). Chemical 
oxidation can occur on endogenous 1,2-diols or similar functional groups,18-21 which can 
then be modified using one of the α-effect nucleophiles. Although carbonyl-based 
bioconjugation reagents are easily synthesized, there are some disadvantages to this 
technique. The bioorthogonality of the reaction is highly dependent on context; although 
aldehydes and ketones do not exist on the surface of proteins, they are found in a number 
of other natural biomolecules that can lower the efficiency and selectivity of the desired 
reaction.14 Secondly, bioconjugation with ketones require acidic conditions for efficient 
labeling, which may not be amenable to more sensitive systems. Lastly, the resulting 
oximes and hydrazones have finite stability, as hydrolysis will occur over time.22 
However, it should be noted that Bertozzi was able to overcome hydrolytic instability by 
trapping the resulting oxime as a Pictet-Spengler product.23 
1.2.2. Staudinger Ligation 
 Ideally, the functional groups necessary for a bioorthogonal reaction are 
completely absent from biological systems. For this reason, reactions involving azides 
have seen widespread applications for bioconjugation methodologies. In addition to their 
absence in native biomolecules,24 azides are small and relatively inert, meaning that their 
installation would result in minimal perturbation of a system.25,26 The first azide-based 
strategy to be reported is the Staudinger ligation, a variant of the classic Staudinger 
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reaction.27 Typically, azides will undergo a Staudinger reaction with phosphine reagents 
to yield amines. However, using specialized phosphine reagents, azides can be converted 
into amides via trapping of the aza-ylide with a nearby ester group. Traceless forms of 
this reaction have also been developed.28-31 It should be noted that azides are capable of 
being reduced by cellular thiols, but the reaction rate is slow. One major disadvantage of 
this technique is that phosphine reagents are susceptible to oxidation. 
1.2.3. Azide-Alkyne Cycloaddition 
 Perhaps the most commonly employed bioorthogonal reaction is the copper-
catalyzed azide-alkyne cycloaddition, commonly abbreviated as CuAAC. In the presence 
of copper (I) species, azides and alkynes undergo a 1,3-dipolar cycloaddition to generate 
a stable triazole product.32,33 The reaction rate for this reaction is relatively fast, and 
occurs under mild conditions. Due to the robust nature of this reaction, it has been 
utilized in a number of other applications throughout several disciplines of chemistry.34-
38  
Unfortunately, copper is toxic to biological systems, but recent reports have 
utilized copper-chelating ligands to reduce copper toxicity.39,40 Alternatively, a copper-
free azide-alkyne cycloaddition has also been developed.41 Rather than lowering the 
transition state energy of the reaction, copper-free cycloaddition occurs by raising the 
energy of the starting material, a feat achieved using highly strained cyclooctyne 
reagents. The reaction is quite useful for in vivo applications, but the reaction is much 
slower than CuAAC and the cyclooctyne reagents are more difficult to synthesize, 
compared to the simple terminal alkynes and primary azides necessary for CuAAC. 
  9 
1.2.4. Tetrazine Ligation 
 One of the fastest available bioorthogonal strategies is the inverse electron 
demand cycloaddition with tetrazines and strained alkenes, such as trans-cyclooctenes, 
cyclopropenes, and norborenes.42-46 The initial cycloaddition is followed by expulsion of 
nitrogen, yielding a stable cyclic product. The rapid nature of this reaction with 
cyclooctenes has resulted in its widespread utilization for in vivo applications. However, 
although the rapid nature of the reaction is useful, the reagents are difficult to synthesize 
and are consequently inaccessible to laboratories that lack experience in synthetic 
organic chemistry. 
1.3. Methods to Install Non-Canonical Amino Acids 
As mentioned above, the chemical modification of proteins is a naturally 
occurring phenomenon that results in altered reactivity and specificity. The study of 
post-translational modifications has been historically difficult due to the dynamic nature 
of protein modifications, and the fact that these changes are relatively small, leading to 
difficult or impossible purification of proteins with the desired modifications. 
Additionally, chemical modification to bestow non-native functionality onto proteins can 
be useful, but the approach has been hindered by a dearth of methods that are 
chemoselective and site-selective. However, the advent of bioorthogonal chemistry has 
given chemical biologists the necessary tools for achieving selectivity in the presence of 
numerous competing biomolecules. 
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1.3.1. Peptide ligation 
 Prior to the development of genetic code expansion, researchers were limited to 
protein samples obtained via indirect, in vitro methodologies. The advent of solid phase 
peptide synthesis (SPPS)47 allowed for the convenient synthesis of peptides without 
regards to limitations imposed by the protein translational machinery. Consequently, 
oligopeptides could be reliably synthesized that contained PTMs or other “unnatural” 
functional groups. In conjunction with native chemical ligation (NCL)48, these 
oligopeptides could be conjugated to the N-terminus of another peptide fragment to 
eventually acquire full-length protein containing a desired modification. In tandem with 
expressed protein ligation (EPL)49, homogenous samples of modified protein became far 
more accessible (Figure 1.5). Despite the accomplishments made through SPPS, NCL, 
and EPL, the techniques are labor intensive and are limited with regard to where the 
protein modification can be installed; this is largely a limitation from SPPS, which can 
only synthesize peptides of a certain length before becoming prohibitively inefficient. 
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O
HN
H2N Protein Intein
HS
CBD
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i.) N to S acyl transfer
ii.) Trans-thioesterificationPhSH
O
SPh
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O
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Peptide
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O
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H2N Protein
O
OH
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HS
Native
Chemical
Ligation
Figure 1.5. Expressed protein ligation (EPL). Native chemical ligation (NCL) is the last step. 
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1.3.2. Genetic Code Expansion 
 A great deal of effort has been put forth in order to exploit the native translational 
machinery for NCAA incorporation. An important observation about protein translation 
is that codons and amino acids are not directly linked, but that the anticodon region of 
the tRNA is crucial for interaction with mRNA codons (refer to Figure 1.1). In other 
words, a tRNA which is misaminoacylated will dutifully install the amino acid in 
question solely based on whenever its appropriate codon appears in the mRNA 
sequence, regardless of which particular amino acid is installed.50,51 Early efforts to 
incorporate unnatural amino acids utilized chemically acylated tRNAs which could be 
used in vitro, but the approach suffered from technical difficulties such as low yields, 
hydrolysis, and competition with endogenous amino acids which require the same 
codon.52-57 Alternatively, in vivo incorporation could be accomplished using canonical 
machinery, but such an approach requires amino acids that must be structurally similar 
to canonical amino acids, and competition between endogenous substrates still occurs 
unless auxotrophic strains are utilized with strictly defined media.58-61 Furthermore, the 
unnatural amino acid will be incorporated at all sites in which the canonical amino acid 
would be coded, thereby limiting the finesse of such an approach. Selected examples of 
amino acid analogues that have been metabolically incorporated are shown in Figure 1.6; 
of the analogues successfully incorporated, methionine surrogates are particularly useful 
for the global installation of bioorthogonal groups.62 
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The laboratory of Peter Schultz reported the first successful, site-specific in vivo 
incorporation of unnatural amino acids in 2001.63 Using a tyrosyl tRNA synthetase-
tRNA pair from Methanococcus jannaschii,64 the Schultz laboratory was able to expand 
the genetic code in Escherichia coli with the non-canonical amino acid O-methyl-L-
tyrosine at UAG codon sites. The MjTyrRS-tRNATyr/CUA pair was optimized for O-
methyl-L-tyrosine using two directed evolution approaches, one to optimize the tRNA 
and another for optimization of the synthetase. To identify an efficient tRNA mutant for 
methyltyrosine incorporation, a randomized library was first subjected to a round of 
negative selection, whereby tRNA capable of being charged by endogenous synthetases 
would die from toxic barnase expression. The survivors of this negative selection would 
Figure 1.6. Non-canonical amino acids incorporated using native machinery. A. Early examples. 
B. Methionine analogues incorporated by Tirrell and Bertozzi. 
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either be non-functional or orthogonal to synthetases native to E. coli. Plasmid DNA 
from the surviving library members was used to transform E. coli harboring a positive 
selection plasmid. Survivors from this round of selection were both functional and 
orthogonal to E. coli synthetases. From here, the chosen tRNA mutant was utilized for 
selection of a synthetase mutant capable of O-methyl-L-tyrosine incorporation. Cells 
possessing the synthetase library were grown in the presence of non-canonical amino 
acid and chloramphenicol (Cm); successful read-through of an in-frame amber codon in 
chloramphenicol acyltransferase (CAT) lead to cell survival in these conditions. 
Survivors were consequently capable of incorporating either the NCAA or any natural 
amino acids with the synthetase library. Replica plating in the presence and absence of 
non-canonical amino acid allowed for isolation of colonies that were only capable of 
growth in the presence of NCAA, and these survivors were further processed and 
resubjected to the selection conditions until an optimized, efficient synthetase mutant 
was isolated. 
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In vivo utilization of the MjTyrRS-tRNATyr/CUA pair has been a successful 
strategy for a number of reasons. Considering that M. jannaschii is a methanogenic 
species of archaea, it belongs in a domain distinct from the prokaryotic E. coli and thus 
Figure 1.7. A. Schultz’s method to evolve efficient, orthogonal tRNATyr/CUA mutants. B. Directed 
evolution to discover mutants capable of aminoacylating tRNATyr/CUA with O-methoxy-L-tyrosine. 
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has molecular machinery that is orthogonal in the latter system.1 More specifically, the 
structural and recognition elements of M. jannaschii tRNA are distinct from those found 
in E. coli, which means the archaeal synthetase will not acylate endogenous tRNA. 
Further, the anticodon region of said tRNA is only loosely associated with MjTyrRS 
during translation, meaning that the anticodon region could be mutated without 
perturbing the affinity for the synthetase-tRNA pair. Also, MjTyrRS lacks an editing 
domain that may interfere with acylation of non-native substrates. Other requirements 
for successful genetic code expansion include successful cytoplasm transport and 
nonexistent acylation of the unnatural amino acid with native machinery. After evolving 
an amber-suppressing MjTyrRS-tRNATyr/CUA pair using randomized libraries, the 
discrepancies between native and orthogonal systems were enhanced, consequently 
boosting the fidelity of the system. 
 Following the initial report, a number of other non-canonical amino acids were 
incorporated using mutant forms of MjTyrRS. These amino acids included an IR-active 
probe for studying protein conformation,65 reactive functionalities for bioconjugation 
and photocrosslinking,66,67 and a photocaged tyrosine for light-responsive modulation of 
enzyme activity.68  
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1.3.3. Exploiting Natural Instances of Genetic Code Expansion 
In some instances, nature has devised methods to expand the genetic code via 
selective suppression of nonsense codons, namely the amber (UAG) and opal (UGA) 
stop codons. The 21st amino acid, selenocysteine, was discovered several decades ago 
and is incorporated via opal suppression; recognition of UGA as a “sense” codon instead 
of a stop codon requires a unique selenocysteine insertion sequence and elongation 
factor.69 Because of these extraneous incorporation components, the utilization of 
selenocysteine machinery is inconvenient for genetic code expansion and its use has not 
been reported. 
Yet another amino acid, pyrrolysine, was discovered in 2001 in methanogenic 
archaea, and was found to be incorporated via amber suppression.70,71 With a unique 
pyrrolysyl-tRNA synthetase and pyrrolysyl tRNA, this amino acid is efficiently installed 
by reading through the UAG amber codon. The incorporation machinery is much 
Figure 1.8.  Selected examples of NCAAs incorporated with MjTyrRS mutants. 
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simpler than selenocysteine incorporation;72 only the synthetase is needed, along with its 
cognate tRNA. Further, its delegation to only a few species of archaea and bacteria mean 
that the pyrrolysine machinery is orthogonal in many systems of interest, both 
prokaryotic and eukaryotic. 
 
 
 
 
 
 
 
Due to the reasons stated above, the discovery of pyrrolysine and its 
incorporation machinery has been a boon to the field of non-canonical amino acids. 
Researchers first began to exploit the wild-type pyrrolysyl-tRNA-synthetase-
Figure 1.9. Structures of pyrrolysine and selenocysteine. 
Figure 1.10. Amino acids incorporated using wild-type PylRS (left) and mutants of PylRS (right). 
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tRNAPyl/CUA (PylRS-PylT) pair to incorporate analogues of pyrrolysine that possess 
functional groups amenable to bioorthogonal chemistry.73-75 Shortly afterward, a number 
of research groups have disclosed the evolution of mutant PylRS-PylT pairs that are 
capable of incorporating a wider variety of substrates.76,77 These non-canonical amino 
acids include Michael acceptors,78 activated reagents for protein labeling,79,80 and post-
translational modification mimics.81 Many more examples are present in the literature, 
and a comprehensive review has recently been published.82 
1.3.4. Beyond Pyrrolysine Analogues: Altered Substrate Specificity of PylRS 
Despite the advances made in genetic code expansion, the pyrrolysyl 
incorporation machinery had thus far been delegated to the incorporation of acylated 
lysine derivatives. Although these have been useful scaffolds for a number of 
applications, a wider variety of amino acid substrates would be desirable. In 2011, our 
group reported the directed evolution of a PylRS capable of incorporating phenylalanine 
and its derivatives, namely p-iodo and p-bromophenylalanine.83 Prior to this discovery, 
the only technology capable of incorporating phenylalanine or tyrosine derivatives was 
the system devised by Schultz and coworkers. Considering that phenylalanyl-tRNA 
synthetase (PheRS) belongs to the same class as PylRS,84 and that they share high 
structural homology, it seems reasonable that PylRS could be engineered to acylate 
phenylalanine and similar substrates. 
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1.4. Conclusions and Outlook 
The discovery of the pyrrolysine incorporation machinery has proven itself to be 
an invaluable tool for discovery in chemical biology. Researchers are now in possession 
of an orthogonal system that naturally suppresses amber stop codons without extraneous 
recognition sequences, and its loose affinity for the native substrate can be easily 
exploited to suit the needs of a particular research project. The past decade has seen 
remarkable advancements in the field of genetic code expansion, and the scientific 
community now has a myriad number of options when research efforts require site-
specific installation of spectroscopic probes, reactive functionalities, and post-
translational modifications. 
 
Figure 1.11.A. Directed evolution of PylRS alters the substrate specificity towards 
phenylalanine and its derivatives. B. Superimposed image of PylRS (2Q7G, green) and PheRS 
(3CMQ, teal) 
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2. GENETIC INCORPORATION OF THIRTEEN NOVEL NON-CANONICAL 
AMINO ACIDS*  
2.1. Introduction 
Site-selective installation of non-canonical amino acids (NCAAs) at an amber 
codon is an efficient approach to synthesize proteins with unique functionalities; 
applications span from basic studies such as protein cellular localization and protein–
protein interaction analysis, to biotechnological applications such as the synthesis of heat 
stable enzymes and therapeutic protein manufacturing.85-89 Two aminoacyl-tRNA 
synthetase–tRNA
 
pairs have been well adapted for the genetic incorporation of NCAAs 
at amber codons in bacteria. One is the tyrosyl-tRNA synthetase–tRNATyr/CUA pair that 
was derived from Methanocaldococcus jannaschii.90-92 The other is the pyrrolysyl-tRNA 
synthetase (PylRS)–tRNAPyl/CUA pair that naturally occurs in some methanogenic 
archaea.93-96 Due to its broad-spectrum orthogonality from bacteria to human cells and 
the fact that it can be easily engineered to target a large variety of NCAAs, including 
natural amino acids with posttranslational modifications, the PylRS– tRNAPyl/CUA pair 
has captivated researchers for the past several years.97-111 One of our major contributions 
to the NCAA research field has been the development of PylRS 
 mutants capable of incorporating a number of phenylalanine derivatives, which are 
substantially different from the structure of pyrrolysine, the native substrate of 
PylRS.85,112,113 More specifically, we have recently shown that a rationally designed, 
_______________________________________________ 
*Tuley, A.; Wang, Y.-S.; Fang, X.; Kurra, Y.; Rezenom, Y. H.; Liu, W. R. Chemical Communications 
2014, 50, 2673. Reproduced by Permission of the Royal Society of Chemistry 
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N346A/C348A mutant of PylRS (PylRS(N346A/C348A)) is capable of incorporating 
seven para- and twelve meta-substituted phenylalanine derivatives at amber codons in 
coordination with tRNAPyl/CUA.
112,113 This broad substrate scope obviates the need to  
undergo the arduous task of discovering a new mutant for each NCAA. Herein we 
demonstrate that PylRS(N346A/C348A) has an even broader substrate scope than 
previously reported.  
Our previous studies revealed a large active site pocket in 
PylRS(N346A/C348A).112 Removal of the N346 side chain amide dismisses the steric 
clash that prevents the binding of the aromatic side chain of phenylalanine and the loss 
of the C348 thiol yields a cavernous pocket capable of binding the para- or meta-
substituted phenylalanine described above. Interestingly, although phenylalanine 
derivatives with small para-substituents have shown to be ineffective substrates for 
PylRS(N346A/C348A), their isomers with meta-substituents act as highly efficient 
substrates of PylRS(N346A/ C348A) for their genetic incorporation at amber 
codons.112,113 In other words, phenylalanine derivatives with para-substituents can only 
be incorporated when they possess large side chains. Upon further inspection, it appears 
that a majority of the vacancy in the active site pocket of PylRS(N346A/C348A) exists 
near the meta position of phenylalanine. Encouraged by our preliminary work, we 
reasoned that PylRS(N346A/C348A) could incorporate phenylalanine derivatives with 
more sterically demanding side chains. 
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2.2. Results and Discussion  
Our investigation began with the synthesis and genetic incorporation of four 
different para-substituted phenylalanine derivatives (1–4 in Figure 2.1.A), each with a 
unique functionality and steric requirement. Synthesis of these derivatives followed the 
same strategy presented in one of our previous reports of the N346A/C348A mutant,112 
with the exception of NCAA 1, which was synthesized using a different approach (refer 
to section 2.4.4 later in this Chapter). These four NCAAs were then tested for their 
tolerability by PylRS(N346A/C348A). An E. coli BL21(DE3) cell that harbors two 
plasmids, pEVOL-pylT-PylRSN346A/C348A and pET- pylT-sfGFP2TAG, was 
employed for the investigation. pEVOL-pylT- PylRSN346A/C348A contains genes 
coding PylRS(N346A/C348A) and tRNAPyl/CUA ; pET-pylT-sfGFP2TAG carries a 
tRNAPyl/CUA coding gene and a non-sequence-optimized superfolder green fluorescent 
protein (sfGFP) gene with an amber mutation in position S2 (sfGFP2TAG). The same 
cells were used in the initial test of the recognition of para-substituted phenylalanine 
derivatives by PylRS(N346A/C348A).112 Growth in minimal media supplemented with 1 
mM IPTG and 0.2% arabinose without NCAA afforded a minimal expression level of 
full-length sfGFP (<0.3 mg L︎-1). Addition of any of 1–4 at 2 mM to the medium all 
promoted full-length sfGFP expression (Fig. 1A). The expression levels for 1–3 are 
comparable to that for para-propargyloxyphenylalanine (7.8 mg L ︎-1),112 and the 
electrospray ionization mass spectrometry analysis of four purified sfGFP variants 
displayed molecular weights that agreed well with the theoretical values corresponding 
to full-length proteins with the first methionine (Figure 2.1.B). 
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The results obtained for 1–4 demonstrate that PylRS(N346A/ C348A) tolerates 
phenylalanine derivative substrates with rigid and bulky substituents at the para 
position. However, ESI-MS data for compound 3 also show a small side peak 
corresponding to the incorporation of phenylalanine, a result we have observed 
previously. The remaining satellite peaks for these compounds correspond to common 
metal adducts in ESI-MS. Additionally, results obtained for 1 demonstrated that both 
meta and para positions can be occupied without detriment to expression levels. These 
Figure	  2.1.	  (A)	  Structures	  of	  1–4	  and	  their	  site-­‐specific	  incorporation	  into	  sfGFP	  at	  its	  S2	  position.	  (B)	  Deconvoluted	  ESI-­‐MS	  spectra	  of	  sfGFP	  variants	  incorporated	  with	  1–4.	  Their	  theoretical	  values	  are	  27	  832	  Da	  for	  1,	  27	  873	  Da	  for	  2,	  27	  886	  Da	  for	  3,	  and	  27	  856	  Da	  for	  4.	  Satellite	  signals	  are	  largely	  due	  to	  metal	  ion	  adducts	  (i.e.	  Li,	  Na,	  K).	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results, coupled with our previous endeavors, led us to wonder if phenylalanine 
derivatives with long-chain meta-substituents could serve as substrates of 
PylRS(N346A/C348A) for genetic incorporation as well. To investigate this hypothesis, 
a series of meta-alkoxy and meta-acyl phenylalanines with substituent chain lengths of 
up to six carbons were synthesized. We chose these specific derivatives because the 
parent NCAAs meta-methoxy-phenylalanine and meta-acetylphenylalanine act as 
efficient substrates for PylRS(N346A/C348A). The synthesis of meta-
alkoxyphenylalanines was straightforward, starting with a published route to obtain 
protected meta-tyrosine, at which point the intermediate was subjected to various alkyl 
halides to afford different derivatives. Acidic deprotection then yielded free amino acids 
as racemic chloride salts. The synthesis of meta-acylphenylalanines was more divergent. 
Alkyl Grignards were added to a solution of meta-tolunitrile, which afforded 
acylbenzenes upon acidic workup. Radical bromination and then displacement with 
diethylacetamidomalonate afforded protected meta-acylphenylalanines that were 
deprotected in 6 M HCl to obtain free amino acids. More detailed synthetic routes can be 
found later in this Section.  
With the desired NCAAs in hand, we thenceforth tested their incorporation 
efficacies at amber codons using the PylRS(N346A/C48A)– tRNAPyl/CUA pair. The E. 
coli cells used for these compounds harbored two plasmids, pEVOL-pylT-PylRSN346A/ 
C348A and pET-pylT-sfGFPS2TAG’. pET-pylT-sfGFPS2TAG’ contains a sequence-
optimized sfGFP with an amber mutation at its S2 position (sfGFPS2TAG’). In 
comparison to the sfGFP2TAG gene in pET-pylT-sfGFP2TAG, sfGFPS2TAG’ has one 
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more alanine residue in front of the amber mutation. Growing this cell in minimal media 
without NCAA yielded a minimal expression level of full-length sfGFP. However, all 
ether NCAAs 6–10 (2 mM) in the medium promoted the synthesis of sfGFP with a 
designated NCAA incorporated (Figure 2.2.A). In comparison to phenylalanine 
derivatives with small meta-substituents such as 5, 6–10 apparently have low 
incorporation levels. Molecular weights of purified sfGFP variants determined by ESI-
MS agreed well with the theoretical values corresponding to a designated NCAA at the 
S2 position and the first methionine hydrolysed (Figure 2.2.B). The removal of the first 
methionine is due to the insertion of alanine after it. A number of smaller signals can be 
observed, but they largely correspond to common metal adducts; the expected masses 
were always the major signal. Compounds 8, 9, and 10 have low solubility; when added 
to the medium at 2 mM, compound 10 was observed to precipitate after 12 h of 
expression. The low sfGFP expression levels for 8, 9, and 10 may be partially due to the 
toxicity of the compounds; indeed, smaller pellet sizes are observed for 8 and 9. 
Although the sfGFP expression level for 9 was very low, the purified sfGFP displayed 
an ESI-MS molecular weight that still matched the theoretical value of sfGFP with 9 
incorporated at S2, indicating that a low concentration of 9 was still sufficient to observe 
incorporation of 9 at the amber mutation site. 
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Overall, addition of ketone derivatives 12–15 at 2 mM to the medium promoted 
high sfGFP expression yields, and longer alkyl lengths had less of an impact on protein 
yields in comparison to the ether series 6–10, though the sfGFP expression levels for 12–
15 are lower than that for 11 (Figure 2.3.A). This series of NCAAs are also readily 
soluble, with no precipitation observed in the medium after overnight incubation. ESI-
Figure	  2.2.	  (A)	  Structures	  of	  5–10	  and	  their	  site-­‐specific	  incorporation	  into	  sfGFP	  at	  its	  S2	  position.	  (B)	  Deconvoluted	  ESI-­‐MS	  spectra	  of	  sfGFP	  variants	  incorporated	  with	  5–10.	  Their	  theoretical	  values	  are	  27	  758	  Da	  for	  5,	  27	  772	  Da	  for	  6,	  27786	  Da	  for	  7,	  27800	  Da	  for	  8,	  27814	  Da	  for	  9,	  and	  27828	  Da	  for	  10.	   
 
  28 
MS analysis of the purified sfGFP variants confirmed high incorporation fidelities of 
12–15 at the S2 site. 
 
 
 
 
 
 
 
 
 
Figure	  2.3.	  (A)	  Structures	  of	  11–15	  and	  their	  site-­‐specific	  incorporation	  into	  sfGFP	  at	  its	  S2	  position.	  (B)	  Deconvoluted	  ESI-­‐MS	  spectra	  of	  sfGFP	  variants	  incorporated	  with	  11–15.	  Their	  theoretical	  values	  are	  27770	  Da	  for	  11,	  27784	  Da	  for	  12,	  27798	  Da	  for	  13,	  27812	  Da	  for	  14,	  and	  27826	  Da	  for	  15.	  Compounds	  13	  and	  14	  show	  small	  signals	  corresponding	  to	  an	  N-­‐terminal	  methionine	  on	  sfGFP.	  Compound	  15	  has	  several	  small	  signals	  attributed	  to	  sodium	  and	  potassium	  adducts.	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Among all of the novel NCAAs that can be taken by PylRS(N346A/ C348A), 2 
has an active azide functionality for a click reaction with an alkyne and 12–15 contain a 
ketone group that potentially reacts with a hydroxylamine. Both functionalities can be 
applied for site-selective labeling of proteins incorporated with 2 and 12–15. Since 
labeling of sfGFP incorporated with 11 with a hydroxylamine dye was demonstrated 
previously,113 we chose to demonstrate the selective labeling of 2 using a 
diarylcyclooctyne dye D1 in this study (Figure 2.4). D1 contains a strained alkyne that 
undergoes a spontaneous reaction with an azide.114 Incubating sfGFP incorporated with 
2 with D1 overnight led to an intensely fluorescently labeled protein; however, the same 
reaction with sfGFP incorporated with 3 did not yield any fluorescently labeled final 
product. This result indicates that genetically incorporated 2 can be applied to site-
specifically introduce biophysical and biochemical probes to proteins for a large variety 
of studies. 
 
 
 
Figure	  2.4.	  Labeling	  of	  sfGFP	  incorporated	  with	  2	  (sfGFP-­‐2)	  and	  sfGFP	  incorporated	  with	  3	  (sfGFP-­‐3)	  with	  dye	  D1.	  The	  top	  panel	  shows	  the	  Coomassie	  blue	  stained	  SDS-­‐PAGE	  gel	  and	  the	  bottom	  panel	  shows	  the	  fluorescent	  image	  of	  the	  same	  gel	  under	  UV	  irradiation	  before	  the	  gel	  was	  stained	  with	  Coomassie	  blue.	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2.3. Conclusion 
In summary, we have shown that thirteen novel NCAAs were genetically 
incorporated into protein at the amber codon in E. coli using the PylRS(N346A/C348A)– 
tRNAPyl/CUA
 
pair. This result, coupled with our previous findings, shows a surprisingly 
broad substrate scope for PylRS(N346A/C348A). Investigations are underway to 
determine aspects of the active site pocket of PylRS(N346A/C348A) that lead to this 
broad substrate spectrum. The current study has great implications in understanding 
amino acid structure tolerance of the protein translation system. The expanded 
genetically encoded NCAA pool can also be applied to generate phage and E. coli 
displayed peptide libraries with expanded chemical moieties for drug discovery, a 
direction we are actively pursuing at the current stage.  
This work was supported in part by the Welch Foundation (grant A-1715), the National 
Science Foundation (grant CHEM-1148684), and the National Institute of Health (grant 
1R01CA161158).  
2.4. Detailed Experimental Protocols 
2.4.1. Superfolder Green Fluorescent Protein Expression 
The constructs used to incorporate compounds 1-4 in this study and 
corresponding protein purification and characterization are identical to previous 
reports.115,116 For compounds 5-15, BL21(DE3) E. coli cells containing pEVOL-PylT-
pylRS-PylRSN346A/C348A (Cmr) and pET-PylT-sfGFP-S2TAG’ (Ampr) vectors were 
grown in 500 mL of LB media with ampicillin (100 µg/mL) and chloramphenicol (34 
µg/mL) until the OD600 reached 1.0-1.3, at which point the cells were pelleted at 4,000 
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r.p.m. for 20 min, then washed and resuspended in 30 mL H2O. The resuspended cells 
were added as 5 mL aliquots to 45 mL of minimal media (33.7 mM Na2HPO4, 22 mM 
KH2PO4, 8.6 mM NaCl, 9.4 mM NH4Cl, 1 mM MgSO4, 0.3 mM CaCl2, 1% glycerol) 
supplemented with 2 mM non-canonical amino acid (NAA), 1 mM IPTG, and 0.2% 
arabinose, at which point protein expression was allowed to occur for 12 h. The cells 
were then pelleted at 4,000 r.p.m. for 20 min, resuspended in lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 8) and lysed via sonication. The crude lysate was then 
centrifuged at 10,000 r.p.m. for 1 hour, and the supernatant was treated with imidazole to 
a final concentration of 10 mM. Next, the supernatant was subsequently incubated with 
Ni2+-NTA resin for 1 hour at 4 ºC. The resin was washed with lysis buffer containing 10 
mM imidazole (3x column volume) and 20 mM imidazole (3x column volume), then 
eluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8). 
The protein was dialyzed against 10 mM Tris buffer, and if necessary, the proteins were 
concentrated using Amicon Ultracel-10k centrifugal filter units. Purity of the proteins 
was confirmed via 15% SDS-PAGE and ESI-MS analysis. Yields were determined using 
a commercially available BCA protein assay kit (Thermo Scientific). 
2.4.2. sfGFP-2 Protein Labeling 
To 16 µl of 1X Phosphate buffered saline (PBS) was added 2 µl sfGFP-2 (3 
mg/mL, 1 µM) and 2 µl Dibenzylcyclooctyne (DBCO) dye (25 mM, DMSO stock 
solution)117 and was allowed to react at room temperature overnight. The protein was 
then precipitated with 180 µl of methanol and left at -20 ºC for 1 h. Next, the 
precipitated protein was centrifuged for 5 min, 14,000 r.p.m. and washed twice with 
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100% methanol. Finally, the residue was resuspended in 20 µl H2O and subjected to 
SDS-PAGE analysis. The control experiment was identical except 4 µl sfGFP-3 (5 
mg/mL, 0.9 µM) was added to 14 µl PBS, followed by 2 µl DBCO dye. 
2.4.3. ESI-MS Analysis of Intact Proteins 
Nanoelectrospray ionization in positive mode was performed using an Applied 
Biosystems QSTAR Pulsar (Concord, ON, Canada) equipped with a nanoelectrospray 
ion source. Solution was flowed at 700 nL/min through a 50 µm ID fused-silica capillary 
that was tapered at the tip. Electrospray needle voltage was held at 2100 V. 
2.4.4. Organic Synthesis 
Reactions were carried out using oven-dried glassware and under an atmosphere 
of argon, where appropriate. Reagents were purchased and used without further 
purification. NMR spectra were obtained with Inova 300 and Mercury 300 MHz 
instruments. 
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2-Amino-3-(benzo[d][1,3]dioxol-5-yl)propanoic Acid Hydrochloride (1) 
To a solution of catechol 16 (5 g, 8.06 mmol) in MeCN (25 mL) was added 
Cs2CO3 (3.93g 12.09 mmol), followed by CH2Cl2 (5.21 mL, 8.06 mmol). The resulting 
mixture was refluxed for 4 hours. After cooling to room temperature, the reaction 
mixture was concentrated and applied to column chromatography, yielding the acetal 17 
in 40% yield (2.12 g).118,119 1HNMR (300 MHz, CDCl3) δ 6.71(m, 3H), 5.93(s, 2H), 
2.27(s, 3H). 
The compound 17 (2.0 g, 14.7 mmol) was dissolved in CCl4 (15 mL), followed 
by addition of NBS (3.12 g, 17.62 mmol) and AIBN (0.337 g, 2.05 mmol). The mixture 
was heated to reflux for 12 h under the protection of argon. After cooling, the precipitate 
was removed via filtration and the filtrate was concentrated and dried under vacuum to 
afford the known compound 18,120 which was used directly in the next step without 
further purification. 
To a solution of compound 18 (3.5 g, 16.27 mmol) in anhydrous acetonitrile (15 
mL) was added diethyl 2-acetamidomalonate (3.88 g, 17.88 mmol), K2CO3 (4.49 g, 
32.53 mmol) and KI (1.0 g, 15.38 mmol). The resulting mixture was heated to reflux for 
12 h under the protection of argon, then cooled to room temperature. The solid was 
filtered, the solvent was removed under reduced pressure, and the residue was purified 
via column chromatograph with hexanes/ethyl acetate (3:1 v/v) as eluent to give the pure 
product 19 (60% yield, 3.42 g). 1HNMR (300 MHz, CDCl3) δ 6.69 (d, J = 8.2Hz, 1 H), 
6.57(d, J = 7.9 Hz, 1 H), 6.47 (s, 1H), 5.92 (s, 2H), 4.30-4.22 (m, 4H), 3.56 (s, 2H), 2.04 
(s, 3H), 1.32-1.23 (m, 6H). 
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A suspension of compound 19 (3.0 g, 8.54 mmol) in 3 M HCl (91.16 mL, 32 eq.) 
was heated to reflux for 16 h before cooling to room temperature. Water was evaporated 
under reduced pressure and the solid was collected. The solid was washed with Et2O (10 
mL × 3) and then dried under vacuum to afford compound 1 as a solid (68% yield, 1.42 
g). 1H NMR (300 MHz, CD3OD) δ 6.78-6.66 (m, 3H), 5.85 (s, 2H), 4.14 (t, J = 6.6 Hz, 1 
H), 3.09 (ABq, J = 15.3, 6.6 Hz, 2 H). 13C NMR (75 MHz, CD3OD) δ 169.8, 148.1, 
147.3, 127.6, 122.6, 109.1, 108.2, 101.1, 53.9, 39.5. 
 
 
 
 
 
(S)-2-Amino-3-(4-(cyclopentylmethoxy)phenyl)propanoic Acid Hydrochloride (3) 
N-Boc-o-methyl-L-tyrosine (20) (1.3 g, 4.4 mmol), cyclopentylmethanol (0.57 
mL, 5.28 mmol), and triphenylphosphine (1.73 g, 6.6 mmol) were added to a round 
bottom flask, then the atmosphere evacuated and replaced with argon. THF (10 mL) was 
then added and the reaction mixture was cooled to 0 ºC, at which point DEAD (1.3 mL, 
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6.6 mmol) was added dropwise and stirred overnight. Upon completion, the reaction 
mixture was concentrated and purified via column chromatography (gradient elution, 
25% to 50% ethyl acetate/hexanes) to give the product 21 in 78% yield (1.3 g). 
This compound was deprotected using the previously described procedure;115 
treatment with 5 mL 1 M NaOH/THF for two hours, followed by Boc deprotection in 5 
mL 4 M HCl/dioxane to give the free amino 3 acid in 97% yield (898 mg), two steps. 1H 
NMR (300 MHz, CD3OD) δ 7.16 (d, J = 8.4 Hz, 2 H), 6.87 (d, J = 8.7, 6.9 Hz, 2 H), 
4.15 (t, J = 5.4 Hz, 1 H), 3.80 (d, J = 6.9 Hz, 2 H), 3.14 (dd, J = 7.8, 5.4 Hz, 2 H), 2.31 
(m, 1 H), 1.82 (m, 2 H), 1.61 (m, 4 H), 1.36 (m, 2 H). 13C NMR (75 MHz, CD3OD) δ 
169.9, 158.9, 130.0, 125.6, 114.6, 71.8, 53.8, 38.9, 35.0, 28.9, 24.9. 
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(S)-2-Amino-3-(4-(but-2-yn-1-yloxy)phenyl)propanoic Acid Hydrochloride (4) 
N-Boc-o-methyl-L-tyrosine (1 g, 3.39 mmol) was treated with 3-bromo-2-
propyne (0.36 mL, 4.06 mmol) and potassium carbonate (1.4 g, 10.2 mmol) in DMF and 
left to react overnight at room temperature. The reaction mixture was then diluted with 
ethyl acetate and washed with 3 M HCl. The organic layers were then dried, 
concentrated, and purified via flash chromatography (gradient elution, 25% to 50% ethyl 
acetate/hexanes) to afford the protected azide 24 in 30% yield (370 mg). Deprotection 
using the protocol listed above gave the title compound 4 in 44% yield (274 mg). 1H 
NMR (300 MHz, CD3OD) δ 7.10 (d, J = 8.7 Hz, 2 H), 6.83 (d, J = 8.7 Hz, 2 H), 4.53 (m, 
2 H), 4.08 (q, J = 7.5 Hz, 1 H), 3.02 (dd, J = 14.7, 7.5 Hz, 2 H), 1.68 (s, 3 H). 13C NMR 
(75 MHz, CD3OD) δ 168.1, 155.8, 128.4, 124.6, 113.3, 81.0, 72.0, 53.9, 52.0, 33.2. 
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(S)-2-Amino-3-(4-(2-azidoethoxy)phenyl)propanoic Acid Hydrochloride (2) 
N-Boc-o-methyl-L-tyrosine 20 (1.8 g, 6.09 mmol) was treated with compound 26 
(1.8 g, 7.31 mmol) and potassium carbonate (3.3 g, 24.4 mmol) in DMF (10 mL) and the 
reaction was heated to 80 ºC. When the reaction was complete based on TLC, the 
reaction mixture was worked up as usual and purified via flash chromatography 
(gradient elution, 25% to 50% ethyl acetate/hexanes) to yield compound 22. 
Deprotection was achieved using 20 mL 1 M LiOH, followed by treatment with 5 mL 4 
M HCl/Dioxane to afford free amino acid 2 (50%, two steps, 873 mg). 1H NMR (300 
MHz, D2O) δ 7.16 (d, J = 8.4 Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 H), 4.11 (m, 3 H), 3.50 (m, 
2 H), 3.11 (m, J = 7.2, 6.9, 5.4 Hz, 2 H). 13C NMR (75 MHz, D2O) δ 169.8, 158.1, 
130.2, 126.4, 114.7, 67.0, 53.8, 49.8, 35.0. 
 
 
 
 
 
Representative Procedure for m-Tyrosine Alkylation 
Methyl 2-Acetamido-3-(3-ethoxyphenyl)propanoate (28) 
To a solution of m-tyrosine121 27 (1.5 g, 6.32 mmol) in DMF (12.64 mL) was 
added K2CO3 (2.84 g, 20.55 mmol), followed by ethyl iodide (0.76 mL, 9.48 mmol). The 
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reaction was stirred at room temperature for 18 h, then quenched with 16 mL H2O and 
79 mL ethyl acetate. The organic layer was extracted three times with 40 mL H2O, then 
dried with sodium sulfate and concentrated. Column chromatography (gradient elution, 
50 to 75% ethyl acetate/hexanes) afforded the compound as a yellow, crystalline solid 
(72% yield, 1.2 g). 1H NMR (300 MHz, CDCl3) δ 7.17 (t, J = 7.8 Hz, 1H), 6.76 (dd, J = 
8.1, 5.7 Hz, 1 H), 6.66 (m, 2 H), 6.04 (d, J = 7.5 Hz, 1 H), 4.85 (dt, J = 7.8, 5.7 Hz, 1 H), 
3.97 (q, J = 6.9 Hz, 2 H), 3.71 (s, 3 H), 3.07 (m, J = 8.1, 5.7 Hz, 2 H), 1.97 (s, 3 H), 1.38 
(t, J = 6.9 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 172.2, 169.7, 159.2, 137.3, 129.6, 
121.5, 115.6, 113.2, 63.4, 53.1, 52.4, 37.9, 23.3, 14.9. 
Methyl 2-Acetamido-3-(3-propoxyphenyl)propanoate (29) 
Synthesized according to the general procedure with m-tyrosine (1.5 g, 6.32 
mmol), DMF (12.64 mL), K2CO3 (2.84g, 20.55 mmol), and n-propyl bromide (0.86 mL, 
9.48 mmol) to yield a yellow, crystalline solid, (68% yield, 1.2 g). 1H NMR (300 MHz, 
CDCl3) δ 7.18 (t, J = 8.1 Hz, 1 H), 6.79 (m, J = 5.7 Hz, 1 H), 6.66 (m, 2H), 5.88 (d, J = 
7.8 Hz, 1 H), 4.87 (dt, J = 7.8, 5.7 Hz, 1H), 3.88 (t, J = 6.6 Hz, 2 H), 3.74 (s, 3 H), 3.09 
(m, J = 8.1, 5.7 Hz, 2 H), 1.99 (s, 3H), 1.79 (sx, J = 7.2 Hz, 2 H), 1.03 (t, J = 7.2 Hz, 3 
H). 13C NMR (75 MHz, CDCl3) δ 172.1, 169.7, 159.3, 137.3, 129.6, 121.4, 115.6, 113.2, 
69.5, 53.1, 52.4, 37.9, 23.2, 22.6, 10.6. 
Methyl 2-Acetamido-3-(3-butoxyphenyl)propanoate (30) 
Synthesized according to the general procedure with m-tyrosine (1.0 g, 4.21 
mmol), DMF (8.42 mL), K2CO3 (1.89g, 13.69 mmol), and n-butyl iodide (0.72 mL, 6.32 
mmol) to yield a yellow, crystalline solid (65% yield, 0.8 g). 1H NMR (300 MHz, 
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CDCl3) δ 7.19 (t, J = 7.8 Hz, 1 H), 6.77 (d, J = 7.2 Hz, 1 H), 6.64 (m, 2 H), 5.87 (d, J = 
6.9 Hz, 1 H), 4.87 (dt, J = 7.8, 5.4 Hz, 1 H), 3.92 (t, J = 6.6 Hz, 2 H), 3.74 (s, 3 H), 3.09 
(dd, J = 8.1, 5.7 Hz, 2 H), 1.99 (s, 3 H), 1.76 (p, J = 6.9, 6.6, 6.3 Hz, 2 H), 1.46 (m, 2 H), 
0.97 (t, J = 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 172.2, 169.7, 159.4, 137.3, 
129.6, 121.4, 115.6, 113.2, 67.7, 53.1, 52.4, 37.9, 31.4, 23.2, 19.3, 13.9. 
Methyl 2-Acetamido-3-(3-(pentyloxy)phenyl)propanoate (31) 
Synthesized according to the general procedure with m-tyrosine (1.5 g, 6.32 
mmol), DMF (12.64 mL), K2CO3 (2.84g, 20.55 mmol), and n-pentyl bromide (1.18 mL, 
9.48 mmol) to yield a yellow, crystalline solid (72% yield, 1.4 g). 1H NMR (300 MHz, 
CDCl3) δ 7.19 (t, J = 8.1 Hz, 1 H), 6.78 (m, 1 H), 6.63 (m, 2H), 5.87 (d, J = 6.9 Hz, 1 
H), 4.82 (dt, J = 7.8, 5.7 Hz, 1H), 3.91 (t, J = 6.6 Hz, 2 H), 3.74 (s, 3 H), 3.10 (dq, J = 
8.1, 6.0 Hz, 2 H), 1.99 (s, 3H), 1.77 (p, J = 7.2, 6.9, 6.6 Hz, 2 H), 1.39 (m, 4 H), 0.93 (t, 
J = 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 172.1, 169.7, 159.2, 137.3, 129.5, 121.2, 
115.5, 113.0, 67.8, 53.1, 52.3, 37.8, 28.9, 28.2, 23.0, 22.4, 14.0. 
Methyl 2-Acetamido-3-(3-(hexyloxy)phenyl)propanoate (32) 
Synthesized according to the general procedure with m-tyrosine (1.0 g, 4.21 
mmol), DMF (8.42 mL), K2CO3 (1.89g, 13.69 mmol), and 1-iodohexane (0.93 mL, 6.32 
mmol) to yield a yellow, crystalline solid (44% yield, 0.6 g). 1H NMR (300 MHz, 
CDCl3) δ 7.18 (t, J = 8.1 Hz, 1 H), 6.77 (dd, J = 8.1, 5.7 Hz, 1 H), 6.63 (m, 2H), 5.88 (d, 
J = 7.2 Hz, 1 H), 4.87 (dt, J = 7.8, 5.7 Hz, 1H), 3.91 (t, J = 6.6 Hz, 1 H), 3.74 (s, 3 H), 
3.09 (m, J = 8.1, 5.7 Hz, 2 H), 1.99 (s, 3H), 1.77 (p, J = 8.1, 6.6 Hz, 2 H), 1.44 (m, 4 H), 
1.33 (m, 4H), 0.91 (t, J = 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 172.2, 169.7, 
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159.4, 137.3, 129.6, 121.4, 115.6, 113.2, 68.0, 53.1, 52.4, 37.9, 31.7, 29.3, 25.8, 23.3, 
22.7, 14.1. 
Representative Procedure for meta-alkoxy Phenylalanine Deprotection 
2-Amino-3-(3-ethoxyphenyl)propanoic Acid Hydrochloride (6) 
A round bottomed flask charged with compound 28 (1.1 g, 4.15 mmol) was 
treated with 14.3 mL 2 M HCl, and the resulting suspension was heated to 100 ºC, which 
was refluxed overnight until complete consumption of starting material as observed on 
TLC. The reaction mixture was then cooled to room temperature and concentrated in 
vacuo. If necessary, the compound was resubjected to the reaction conditions due to the 
persistence of methyl ester and/or N-acyl amide signals in 1H and 13C NMR. The title 
compound was obtained as a white solid in 45% yield (463 mg). 1H NMR (300 MHz, 
D2O) δ 7.35 (t, J = 7.8 Hz, 1 H), 6.93 (m, 3 H), 4.31 (t, J = 7.5 Hz 1 H), 4.11 (q, J = 6.9 
Hz, 2 H), 3.24 (dq, J = 14.7, 5.7 Hz, 2 H), 1.37 (t, J = 6.9 Hz, 3 H). 13C NMR (75 MHz, 
D2O) δ 171.4, 158.3, 135.6, 130.4, 122.1, 115.5, 114.1, 64.2, 54.0, 35.5, 13.8.  
2-Amino-3-(3-propoxyphenyl)propanoic Acid Hydrochloride (7) 
Prepared according to the general procedure using compound 29 (1.0 g, 3.58 
mmol) and 12.34 mL 2 M HCl. Obtained as a white solid in 43% yield (402 mg). 1H 
NMR (300 MHz, D2O) δ 7.34 (t, J = 7.5 Hz, 1 H), 6.90 (m, 3 H), 4.29 (t, J = 5.4 Hz, 1 
H), 3.97 (t, J = 6.6 Hz), 3.21 (dd, J = 14.7, 5.7 Hz, 2 H), 1.73 (sx, J = 7.5, 7.2, 6.9, 6.6 
Hz, 2 H), 0.96 (t, J = 7.5, 3 H). 13C NMR (75 MHz, D2O) δ 171.3, 158.5, 135.5, 130.3, 
122.0, 115.5, 114.1, 70.1, 53.9, 35.4, 21.7, 9.5. 
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2-Amino-3-(3-butoxyphenyl)propanoic Acid Hydrochloride (8) 
Prepared according to the general procedure using compound 30 (0.8 g, 2.73 
mmol) in 9.4 mL 2 M HCl to obtain the title compound in 30% yield (222 mg). 1H NMR 
(300 MHz, DMSO) δ 8.53 (s, 2 H), 7.21 (t, J = 7.8 Hz, 1 H), 6.89 (s, 1 H), 6.82 (d, J = 
7.8 Hz, 2 H), 4.14 (t, J = 5.4 Hz, 1 H), 3.94 (t, J = 6.6 Hz, 2 H), 3.12 (d, J = 6.0 Hz, 2 
H), 1.69 (p, J = 7.5, 6.9, 6.6 Hz, 2 H), 1.45 (sx, J = 7.5, 7.2 Hz, 2 H), 0.93 (t, J = 7.2 Hz, 
3 H). 13C NMR (75 MHz, DMSO) δ 170.2, 158.7, 136.4, 129.5, 121.5, 115.6, 113.1, 
66.9, 53.1, 35.5, 30.8, 18.8, 13.7. 
2-Amino-3-(3-(pentyloxy)phenyl)propanoic Acid Hydrochloride (9) 
Prepared according to the general procedure using compound 31 (1.0 g, 3.25 
mmol) in 11.2 mL 2 M HCl to obtain the title compound in 61% yield (570 mg). 1H 
NMR (300 MHz, DMSO) δ 8.49 (s, 2 H), 7.21 (t, J = 7.5 Hz, 1 H), 6.88 (s, 1 H), 6.82 (d, 
J = 8.1 Hz, 2 H), 4.14 (t, J = 6.0 Hz, 1 H), 3.94 (t, J = 6.6 Hz, 1 H), 3.11 (d, J = 6.0 Hz, 2 
H), 1.71 (p, J = 6.9, 6.6, 6.3 Hz, 2 H), 1.36 (m, 4 H), 0.89 (t, J = 6.6 Hz, 3 H). 13C NMR 
(75 MHz, DMSO) δ 170.2, 158.7, 136.4, 129.5, 121.6, 115.6, 113.1, 67.2, 53.0, 35.6, 
28.4, 27.7, 21.9, 13.9.  
2-Amino-3-(3-(hexyloxy)phenyl)propanoic Acid Hydrochloride (10) 
Prepared according to the general procedure using compound 32 (0.6 g, 1.87 
mmol) in 6.44 mL 2 M HCl to yield the compound as a white solid in 65% yield (367 
mg). 1H NMR (300 MHz, DMSO) δ 8.48 (s, 3 H), 7.21 (t, J = 7.8 Hz, 1 H), 6.88 (s, 1 H), 
6.82 (d, J = 7.8 Hz, 2 H), 4.13 (m, J = 5.1, 4.5 Hz, 1 H), 3.93 (t, J = 6.6 Hz, 2 H), 3.10 
(d, J = 6.3 Hz, 2 H), 1.69 (p, J = 7.8, 6.6 Hz, 2 H), 1.41 (m, 2 H), 1.29 (m, 4 H), 0.88 (t, 
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J = 6.6 Hz, 3 H). 13C NMR (75 MHz, DMSO) δ 170.2, 158.7, 136.3, 129.5, 121.5, 115.6, 
113.1, 67.2, 53.0, 35.6, 31.0, 28.7, 25.2, 22.1, 13.9. 
 
 
 
 
 
Representative Procedure for Grignard Addition to m-Tolunitrile 
1-(m-Tolyl)propan-1-one (34) 
Ethyl magnesium bromide (1 M/THF, 85.36 mL, 85.36 mmol) was added 
dropwise to a solution of m-tolunitrile (10.25 mL, 85.36 mmol) and copper (I) iodide 
(40.64 mg, 0.213 mmol) in anhydrous THF (170.72 mL) under argon. After stirring for 
22 h, the reaction was quenched with approx. 5 mL 1 M HCl at 0 ºC and stirred for 4 h, 
allowing the reaction to warm to room temperature. The resulting layers were separated 
and the organic layer was dried with MgSO4, filtered, and concentrated. The crude, 
yellow oil was purified via silica gel chromatography (gradient, 0 to 10% EtOAc/Hex) to 
afford the known compound122 34 in 94% yield (9.4 g) as a yellow oil. 1H NMR (300 
MHz, CDCl3) δ 7.76 (m, 1H), 7.38 (m, 3H), 2.99 (q, J = 7.2 Hz, 2H), 2.41 (s, 3H), 1.22 
(t, J = 7.2 Hz, 3H). 
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1-(m-Tolyl)butan-1-one (35) 
Prepared according to the general procedure with Propylmagnesium bromide (2 
M/THF, 42.68 mL, 85.36 mmol), m-tolunitrile (10.25 mL, 85.36 mmol), and CuI (40.64 
mg, 0.213 mmol) to yield the known compound123 in 96 % yield (13.24 g). 1H NMR 
(300 MHz, CDCl3) δ 7.77 (s, 2H), 7.36 (s, 2H), 2.94 (t, J = 7.2 Hz, 2H), 2.41 (s 3H), 
1.76 (sx, J = 7.2 Hz, 2H), 1.00 (t, J = 7.2 Hz, 3H). 
1-(m-Tolyl)pentan-1-one (36) 
Prepared according to the general procedure with butylmagnesium chloride (2 
M/THF, 42.68 mL, 85.36 mmol), m-tolunitrile (10.25 mL, 85.36 mmol), and CuI (40.64 
mg, 0.213 mmol) to yield the known compound124 in 76% yield (11.43 g). 1H NMR (300 
MHz, CDCl3) δ 7.75 (m, 2H), 7.34 (m, 2H), 2.95 (t, J = 7.2 Hz, 2H), 2.41 (s, 3H), 1.71 
(p, J = 7.5 Hz, 2H), 1.41 (sx, J = 7.2 Hz, 2H), 0.95 (t, J = 7.5 Hz, 3H). 
1-(m-Tolyl)hexan-1-one (37) 
Prepared according to the general procedure with Pentylmagnesium bromide (1 
M/THF, 42.68 mL, 85.36 mmol), m-tolunitrile (10.25 mL, 85.36 mmol), and CuI (40.64 
mg, 0.213 mmol) to yield the known compound125 in 94% yield (15.3 g). 1H NMR (300 
MHz, CDCl3) δ 7.74 (m, 1H), 7.46 (s, 1H), 7.37 (m, 2H), 2.94 (t, J = 6.9 Hz, 2H), 2.41 
(s, 3H), 1.73 (p, J = 7.2 Hz, 2H), 1.35 (m, 4H), 0.91 (t, J = 6.6 Hz, 3H). 
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Representative Procedure for the Synthesis of Protected Ketones 
Diethyl 2-Acetamido-2-(3-propionylbenzyl)malonate (38) 
To a solution of m-Keto toluene 34 (8.0 g, 53.98 mmol) in CCl4 (134.95 mL) was 
added NBS (10.57 g, 59.38 mmol) and AIBN (2.67 g, 16.19 mmol), and the resulting 
suspension was refluxed overnight. Upon completion, the reaction was filtered and 
concentrated, and the resulting crude material was subjected to the next step without 
further purification. 
A round-bottom flask was charged with brominated 34 (4.24 g, 19.09 mmol), 
diethyl 2-acetamidomalonate (3.73 g, 17.18 mmol), K2CO3 (5.28 g, 38.18 mmol), and KI 
(3.17 g, 19.09 mmol), followed by 119.3 mL of MeCN, and the resulting suspension was 
heated to reflux and stirred overnight. Upon completion, the reaction was cooled to room 
temperature, filtered with celite, and concentrated. Purification via silica gel 
chromatography (gradient elution, 0 to 30% EtOAc/Hex) afforded 38 as a yellow solid 
in 58% yield (3.6 g). 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J = 7.8 Hz, 1 H), 7.64 (s, 1 
H), 7.36 (t, J = 7.8, 7.5 Hz, 1 H), 7.20 (d, J = 8.4 Hz, 1 H), 6.52 (s, 1 H), 4.28 (q, J = 7.2, 
6.9 Hz, 4 H), 2.96 (q, J = 7.2 Hz, 2 H), 2.05 (s, 3 H), 1.31 (t, J = 7.2 Hz, 6 H), 1.21 (t, J 
= 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 200.5, 169.3, 167.4, 137.0, 136.0, 134.5, 
129.3, 128.6, 127.1, 67.2, 63.0, 37.7, 31.9, 23.1, 14.1, 8.3.  
Diethyl 2-Acetamido-2-(3-butyrylbenzyl)malonate (39) 
Synthesized according to the general procedure with ketone 35 (8.0 g, 49.31 
mmol), NBS (9.65 g, 54.24 mmol), AIBN (2.43 g, 14.79 mmol), and 123.28 mL CCl4. 
The crude product was subjected to the next step without further purification. 
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Malonate synthesis was performed according to the general procedure using 
brominated 35 (5.73 g, 23.75 mmol), diethyl 2-acetamidomalonate (4.64 g, 21.37 mmol), 
K2CO3 (6.56 g, 47.5 mmol), KI (3.94 g, 23.75 mmol), and 148 mL MeCN. 37% yield, 
2.9 g. 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 7.8 Hz, 1 H), 7.63 (s, 1 H), 7.34 (t, J = 
7.5 Hz, 1 H), 7.20 (d, J = 7.2 Hz, 1 H), 6.52 (s, 1 H), 4.28 (q, J = 7.2, 6.9 Hz, 4 H), 2.89 
(t, J = 7.2 Hz, 2 H), 2.05 (s, 3 H), 1.75 (sx, J = 7.5, 7.2 Hz, 2 H), 1.31 (t, J = 7.2 Hz, 6 
H), 0.99 (t, J = 7.5 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 200.1, 169.3, 167.4, 137.2, 
136.0, 134.5, 129.4, 128.6, 127.1, 67.2, 63.0, 40.6, 37.7, 23.1, 17.8, 14.1, 14.0. 
Diethyl 2-Acetamido-2-(3-pentanoylbenzyl)malonate (40) 
Synthesized according to the general procedure with ketone 36 (9.5 g, 53.9 
mmol), NBS (10.55 g, 59.29 mmol), AIBN (2.66 g, 16.17 mmol), and 134.75 mL CCl4. 
The crude product was subjected to the next step without further purification. 
Malonate synthesis was performed according to the general procedure using 
brominated 36 (6.26 g, 24.53 mmol), diethyl 2-acetamidomalonate (4.79 g, 22.08 mmol), 
K2CO3 (6.78 g, 49.07 mmol), KI (4.07 g, 24.53 mmol), and 153.3 mL MeCN. 51% yield 
as a yellow solid (4.4 g). 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.1 Hz, 1 H), 7.62 
(s, 1 H), 7.36 (t, J = 7.8 Hz, 1 H), 6.52 (s, 1 H), 4.28 (q, J = 7.2 Hz, 4 H), 3.7 (s, 2 H), 
2.92 (t, J = 7.5 Hz, 2 H), 2.05 (s, 3 H), 1.70 (p, J = 7.8, 7.5, 7.2 Hz, 2 H), 1.38 (p, J = 
7.8, 7.5, 7.2 Hz, 2 H), 1.31 (t, J = 6.9, 7.2 Hz, 6 H), 0.95 (t, J = 7.2 Hz, 3 H). 13C NMR 
(75 MHz, CDCl3) δ 200.2, 169.3, 167.4, 137.2, 135.9, 134.5, 129.3, 128.6, 127.1, 67.2, 
62.9, 38.4, 37.7, 26.4, 23.1, 22.5, 14.0. 
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Diethyl 2-Acetamido-2-(3-hexanoylbenzyl)malonate (41) 
Synthesized according to the general procedure with ketone 37 (10.0 g, 52.55 
mmol), NBS (10.3 g, 57.81 mmol), AIBN (2.59 g, 15.77 mmol), and 131.38 mL CCl4. 
The crude product was subjected to the next step without further purification. 
Malonate synthesis was performed according to the general procedure using 
brominated 37 (5.73 g, 23.75 mmol), diethyl 2-acetamidomalonate (4.52 g, 20.79 mmol), 
K2CO3 (6.39 g, 46.21 mmol), KI (3.84 g, 23.11 mmol), and 144.44 mL MeCN. 37% 
yield as a yellow solid (3.1 g). 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 6.6 Hz, 1 H), 
7.62 (s, 1 H), 7.36 (t, J = 7.5 Hz, 1 H), 7.20 (d, J = 7.5 Hz, 1 H), 6.52 (s, 1 H), 4.28 (q, J 
= 7.2 Hz, 4 H), 3.71 (s, 2 H), 2.91 (t, J = 7.5 Hz, 2 H), 2.05 (s, 3 H), 1.72 (m, 2 H), 1.34 
(m, 4 H), 1.31 (m, 6 H), 0.91 (t, J = 6.6 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 200.2, 
169.4, 167.4, 137.2, 135.9, 134.5, 129.3, 128.6, 127.1, 67.2, 62.9, 38.7, 37.7, 31.6, 24.0, 
23.1, 22.6, 14.1. 
Representative Procedure for Malonate Deprotection 
2-Amino-3-(3-propionylphenyl)propanoic Acid Hydrochloride (12) 
A suspension of 38 (1.0 g, 2.75 mmol) in 6 M HCl was refluxed overnight, until 
disappearance of protecting groups was verified via 1H NMR. The resulting solution was 
concentrated in vacuo to yield 12 as a yellow solid (36% yield, 256 mg). 1H NMR (300 
MHz, D2O) δ 7.93 (d, J = 6.9 Hz, 1 H), 7.87 (s, 1 H), 7.55 (m, 2 H), 4.16 (t, J = 7.2 Hz, 
1 H), 3.30 (dq, J = 14.1, 5.7 Hz, 2 H), 3.09 (q, J = 7.2 Hz, 2 H), 1.14 (t, J = 6.9 Hz, 3 H). 
13C NMR (75 MHz, D2O) δ 206.4, 172.4, 136.8, 135.1, 134.4, 129.3, 128.7, 127.5, 54.8, 
35.7, 31.9, 7.5. 
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2-Amino-3-(3-butyrylphenyl)propanoic Acid Hydrochloride (13) 
Synthesized according to the representative procedure using 39 (1.0 g, 2.65 
mmol) in 9.14 mL 6 M HCl. 80% yield, 576 mg. 1H NMR (300 MHz, D2O) δ 7.95 (d, J 
= 7.2 Hz, 1 H), 7.85 (s, 1 H), 7.53 (m, 2 H), 4.28 (t, J = 7.2 Hz, 1 H), 3.31 (dq, J = 14.7, 
5.7 Hz, 2 H), 3.02 (t, J = 7.2 Hz, 2 H), 1.66 (q, J = 7.2 Hz, 2 H), 0.92 (t, J = 7.2 Hz, 3 
H). 13C NMR (75 MHz, D2O) δ 206.1, 171.5, 136.9, 134.8, 134.5, 129.4, 128.8, 127.8, 
54.2, 40.4, 35.4, 17.6, 12.8. 
2-Amino-3-(3-pentanoylphenyl)propanoic Acid Hydrochloride (14) 
Synthesized according to the representative procedure using 40 (1.08 g, 2.75 
mmol) in 9.48 mL 6 M HCl. 29% yield, 200 mg. 1H NMR 7.96 (dt, J = 7.2 Hz, 1 H), 
7.87 (s, 1 H), 7.58 (m, 2 H), 4.31 (t, J = 7.2 Hz, 1 H), 3.35 (dq, J = 14.7, 5.7 Hz, 2 H), 
3.07 (t, J = 7.2 Hz, 2 H), 1.65 (p, J = 7.2 Hz, 2 H), 1.34 (sx, J = 7.5, 7.2 Hz, 2 H), 0.91 
(t, J = 7.2 Hz, 3 H). 13C NMR (75 MHz, D2O) δ 206.2, 171.5, 136.9, 134.7, 134.5, 129.4, 
128.8, 127.8, 54.2, 38.3, 35.4, 26.2, 21.6, 13.0. 
2-Amino-3-(3-hexanoylphenyl)propanoic Acid Hydrochloride (15) 
Synthesized according to the representative procedure using 41 (1.03 g, 2.55 
mmol) in 8.79 mL 6 M HCl. 34% yield, 229 mg. 1H NMR (300 MHz, D2O) δ 7.95 (d, J 
= 7.2 Hz, 1 H), 7.87 (s, 1 H), 7.57 (m, 2 H), 4.22 (t, J = 7.2 Hz, 1 H), 3.33 (dq, J = 14.7, 
7.8 Hz, 2 H), 3.08 (t, J = 7.2 Hz, 2 H), 1.68 (m, 2 H), 1.33 (m, 4 H), 0.86 (m, 3 H). 13C 
NMR (75 MHz, D2O) δ 205.2, 181.6, 139.1 136.3, 134.6, 128.8, 128.7, 126.3, 57.3, 
40.9, 30.7, 23.8, 21.8, 13.3. 
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2.4.5. sfGFPS2TAG’ Protein Sequence 
MAXKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFIC
TTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKD
DGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADK
QKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKD
PNEKRDHMVLLEFVTAAGITHGMDELYKGSHHHHHH 
X denotes an amber stop codon for NAA incorporation in this study. 
Compounds 5-15 were expressed using the sequence provided above. sfGFP 
expression of 1-4 used a sequence described previously.115,116 
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3. A GENETICALLY ENCODED ALDEHYDE FOR RAPID PROTEIN LABELING*  
3.1. Introduction 
Although the aldehyde is one of the most versatile chemical functionalities and 
participates in a variety of useful chemical reactions,23,126-130 it is not a part of the 20 
canonical amino acids. To harness the unique reactivity of aldehydes with hydrazine and 
hydroxylamine dyes for protein labeling, aldehyde tags have been introduced into 
proteins by oxidizing an N-terminal serine or via enzymatic modifications of preinstalled 
substrate peptides.20,131-135 The N-terminal oxidation approach can only be applied in 
vitro and the enzymatic approach is generally confined for the aldehyde installation at 
the two protein termini. To genetically encode the keto functionality at any chosen site in 
a protein, several ketone-containing non-canonical amino acids (NCAAs) have been 
designed and incorporated into proteins in living cells using the amber suppression 
approach.136-140 However, a method for the genetic incorporation of an aldehyde-
containing NCAA has not been developed. We are interested in a genetically encoded, 
aldehyde-containing NCAA due to its superior reactivity with respect to ketone- 
containing NCAAs, and the observation that aniline can selectively enhance the reaction 
kinetics of the aldehyde–hydroxylamine/hydrazine condensation.141-144  
 
 
 
_______________________________________________ 
*Tuley, A.; Lee, Y.-J.; Wu, B.; Wang, Z. U.; Liu, W. R. Chemical Communications 2014, 50, 7424. 
Reproduced by Permission of the Royal Society of Chemistry 
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3.2. Results and Discussion 
In our previous studies, we revealed that a mutant pyrrolysyl-tRNA synthetase 
with mutations N346A/C348A (PylRS(N346A/C348A)) recognizes a number of 
phenylalanine derivatives including meta-acetylphenylalanine (2 in Figure 3.1.A) and, in 
coordination with tRNAPyl/CUA , directs their genetic incorporation at amber mutation 
sites in Escherichia coli and mammalian cells.83,115,116,145,146 Given the size similarity 
between 2 and meta-formyl-phenylalanine (1), and the ability of this mutant enzyme to 
accept diverse meta-substituted phenylalanine substrates, we anticipated that this same 
 
 
  
 
Figure	  3.1.	  (A)	  Structures	  of	  1–4.	  (B)	  The	  synthetic	  route	  of	  1.	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mutant enzyme would also accept 1 as its substrate. To test this prospect, 1 was readily 
prepared in a high yield by a three-step synthesis (Figure 3.1.B). Its acceptance as a 
substrate of PylRS(N346A/C348A) was then examined. An E. coli BL21(DE3) cell that 
harbored two plasmids, pEVOL-pylT-PylRS(N346A/C348A) and pET-pylT-
sfGFP2TAG, was employed for the investigation. Plasmid pEVOL-pylT- 
PylRS(N346A/C348A) contains genes coding both PylRS(N346A/C348A) and 
tRNAPyl/CUA . Plasmid pET-pylT-sfGFP2TAG carries a tRNAPyl/CUA coding gene and a 
sequence-optimized superfolder green fluorescent protein (sfGFP) gene with an amber 
mutation at its S2 position. Growing cells in M9 minimal medium supplemented with 
1% glycerol, 1 mM IPTG and 0.2% arabinose, but without 1, afforded a minimal 
expression level of full-length sfGFP (<1 mg L︎
-1
). Providing 1 at 2 mM into the medium 
promoted full-length sfGFP expression (Figure 3.2.A). The expression level is 
comparable to that of para-propargyloxy-phenylalanine (ProY), and the electrospray 
ionization mass spectrometry analysis of the purified 1-containing sfGFP displayed a 
molecular weight that agreed well with its theoretical value (Figure 3.2.B). Moreover, 
compound 1 is not toxic to E. coli cells, as phenotypes and cell pellets are comparable to 
control experiments. 
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Dawson et al. previously showed that aniline could serve as an excellent catalyst 
for speeding the imine formation of aldehydes with hydroxylamines and hydrazines. To 
demonstrate this catalytically rapid reaction on proteins, sfGFP with 1 incorporated at its 
N149 position (sfGFP-1) was expressed and then applied to a Förster resonance energy 
transfer (FRET)-based kinetic investigation of its reaction with a coumarin dye 3,139,147 
in the presence of 100 mM aniline and at pH 7 using a fluorescence spectrophotometer 
(Figure 3.1.A). 3 has an excitation wavelength at 417 nm and emits at 476 nm. Its 
emitted light falls in the range of excitation lights of sfGFP that emits at 510 nm.148 The 
reaction of sfGFP-1 with 3 will place 3 in a close locality of the sfGFP fluorophore for 
FRET. All kinetic analyses were carried out under pseudo-first-order conditions in 
which 3 was at least in 5-fold excess in comparison to sfGFP-1. Data collected under 
these conditions were well fitted to a single exponential increase equation F = F1 – F2 x︎ 
e(- ︎k’ x ︎t), where F was the detected fluorescent signal at a given time, F1 was the final 
Figure	  3.2.	  (A)	  The	  site-­‐specific	  incorporation	  of	  1	  into	  sfGFP	  at	  its	  S2	  position.	  Cells	  transformed	  with	  pEVOL-­‐PylRS(N346A/C348A)	  and	  pET-­‐pylT-­‐sfGFP2TAG	  were	  grown	  under	  conditions	  with	  or	  without	  a	  NCAA	  supplement.	  (B)	  The	  deconvoluted	  ESI-­‐MS	  spectrum	  of	  the	  purified	  1-­‐containing	  sfGFP.	  Its	  theoretical	  value	  is	  27	  756	  Da.	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fluorescence, F1-F2 was the background fluorescent signal, and k’ was the apparent 
pseudo first-order rate constant (Figure 3.3.A). The determined k’ values were plotted 
against the concentrations of 3 and fitted to the equation k’ = k ︎ [3] + C, where k was a 
second-order rate constant for the reaction of sfGFP-1 with 3 (inset of Figure 3.3.A). 
 
 
 
Figure	  3.3.	  A)	  Fluorescent	  intensities	  as	  a	  function	  of	  time	  for	  reactions	  of	  0.05	  μM	  sfGFP-­‐1	  (colored	  in	  blue)	  and	  0.05	  μM	  sfGFP-­‐2	  (colored	  in	  red)	  with	  10	  μM	  3	  in	  the	  presence	  of	  100	  mM	  aniline	  and	  at	  pH	  7.	  Presented	  in	  the	  inset	  is	  the	  linear	  dependence	  of	  the	  determined	  pseudo	  first-­‐order	  rate	  constants	  for	  the	  reaction	  of	  0.1	  μM	  sfGFP-­‐1	  with	  3	  on	  the	  concentrations	  of	  3.	  (B)	  Gel	  imaging	  analysis	  of	  labeling	  of	  sfGFP-­‐1	  and	  sfGFP-­‐2	  with	  4	  with	  different	  incubation	  times.	  For	  both	  sfGFP-­‐1	  and	  sfGFP-­‐2,	  labeling	  was	  carried	  out	  under	  conditions	  with	  8	  μM	  protein,	  10	  μM	  4,	  100	  mM	  aniline,	  and	  pH	  7.	  Reactions	  were	  quenched	  with	  the	  addition	  of	  2	  mM	  benzaldehyde	  at	  indicated	  times	  and	  analyzed	  by	  denaturing	  SDS-­‐PAGE.	  The	  top	  panel	  shows	  proteins	  with	  Coomassie	  blue	  staining	  and	  the	  bottom	  panel	  presents	  the	  fluorescent	  imaging	  of	  the	  same	  gel	  before	  Coomassie	  blue	  staining.	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The calculated second-order rate constant was 182 ± 12 M ︎-1 s ︎-1. This determined rate 
constant is comparable to what Dawson et al. reported for aniline-catalyzed 
bioconjugation, and is among one of the most rapid bioorthogonal reactions.42,46,78,141-
144,149-151 We also carried out the kinetic analysis in the absence of aniline. However, no 
obvious signal changes were observed when 0.1 µM sfGFP-1 reacted with 4 µM 3 in a 
period of 2 h, indicating very slow kinetics of the sfGFP-1 reaction with 3 in the absence 
of aniline and at pH 7. We also tried much higher concentrations of 3 to speed up the 
reaction rate. However, the background fluorescence from 3 under these conditions was 
too high to collect reliable data. As a comparison, a sfGFP variant with 2 incorporated at 
its N149 position (sfGFP-2) was also expressed and used for kinetic investigation of its 
reaction with 3 in the presence of 100 mM aniline and at pH 7. As shown in Fig. 3A, 
under the tested conditions of 0.05 µM sfGFP-2 and 10 µM 3, no obvious signal increase 
due to the sfGFP-2 reaction with 3 was observed in a period of 30 min. The fluorescence 
decrease was caused by the bleaching effect of the excitation light.  
The different labeling kinetics of sfGFP-1 and sfGFP-2 were also examined by 
fluorescent imaging of SDS-PAGE analyzed 4-labelled products. Both sfGFP-1 and 
sfGFP-2 at 8 µM were incubated with 10 µM 4 in the presence of 100 mM aniline and at 
pH 7. Reactions were quenched at different times and analyzed by denaturing SDS-
PAGE to remove the intrinsic fluorescence of sfGFP. Fluorescent imaging of two 
proteins at different labeling times clearly showed that sfGFP-1 was efficiently labeled 
at 25 min but sfGFP-2 was minimally labeled even at 2 h. Labeling could also be 
achieved in the absence of aniline, though reaction times were significantly longer (Fig. 
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3.6 in section 3.4.3). Once again, sfGFP-1 showed superior labeling with respect to 
sfGFP-2. This result shows that, in systems where aniline may be toxic, labeling can still 
be achieved without it or at much lower concentrations.  
With the demonstration of fast labeling kinetics of 1 with hydroxylamine dyes, 
we then proceeded to test the conditions for labeling proteins that bear site-specifically 
incorporated 1 in living cells. Plasmid pEVOL-pylT-PylRS(N346A/C348A) and a 
previously constructed plasmid, pETDuet-OmpXTAG, were used to transform E. coli 
BL21 cells. The latter plasmid contained a gene coding for an E. coli outer membrane 
protein OmpX,78 with an AAAXAA (A denotes alanine and X denotes an amber 
mutation) insertion between two extracellular residues, 53 and 54. The transformed cells 
were grown in M9 minimal medium supplemented with 1% glycerol, 1 mM IPTG, 0.2% 
arabinose, and 2 mM 1 or 2 to express OmpX with 1 or 2 incorporated (OmpX-1 or 
OmpX-2). Cells were then harvested and labeled with 4 in the presence of 100 mM 
aniline and at pH 7 for 1 h. After labeling, cells were washed with PBS buffer six times 
to remove the residual dye and then imaged by fluorescent microscopy. Cells grown in 
the absence of 1 or 2 were used as a control. As shown in Figure 3.4, 4 specifically 
labeled cells expressing OmpX-1 and OmpX-2 were observed, but not for cells in the 
control experiment. Although cells expressing OmpX-2 were fluorescently labeled, their 
intensities are weaker than those of cells expressing OmpX-1, indicating a slower 
labeling kinetics of OmpX-2. However, we have found that this concentration of aniline 
is toxic to E. coli, which underscores the need for developing less toxic catalysts for this 
reaction.  
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3.3. Conclusion 
In summary, we reported the genetic incorporation of a readily synthesized 
aldehyde-containing NCAA and demonstrated its fast labeling kinetics with 
hydroxylamine dyes in the presence of the aniline catalyst. This rapid labeling approach 
was also successfully applied to label a membrane protein on the E. coli extracellular 
Figure	  3.4.	  Selective	  labeling	  of	  E.	  coli	  cells	  expressing	  OmpX-­‐1	  and	  OmpX-­‐2.	  The	  labeling	  was	  carried	  out	  in	  the	  presence	  of	  100	  mM	  aniline	  and	  at	  pH	  7	  for	  1	  h.	  The	  top	  panel	  shows	  bright	  field	  imaging	  of	  E.	  coli	  cells,	  the	  middle	  panel	  shows	  green	  fluorescent	  imaging	  of	  same	  cells,	  and	  the	  bottom	  panel	  shows	  their	  composite	  images	  (scale	  bars	  are	  10	  μm).	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surface. Although genetically encoded ketone-containing NCAAs were reported 
previously, labeling of proteins with these NCAAs typically suffers low labeling 
efficiencies, attributing to slow labeling kinetics of ketones. This work resolves this 
obstacle. Given that a large variety of hydroxylamine and hydrazine dyes are 
commercially available, as well as the existence of numerous aldehyde-based 
bioconjugation strategies,15-17,152-161 we anticipate that this approach will be quickly 
adopted by others for studies such as protein folding/dynamics, protein–ligand 
interactions, high throughput drug discovery, etc.  
3.4. Detailed Experimental Protocols 
Organic synthesis was performed in oven-dried glassware under an argon 
atmosphere, and reagents were purchased and used without further purification. NMR 
spectra were obtained using Inova-300, Mercury-300, and Inova-500 instruments. 
Centrifugation was performed using a Sorvall Superspeed RC2-B automatic refrigerated 
centrifuge. Cell lysis was achieved with a VWR Scientific Branson Sonifier 450. 
Fluorometer data was obtained on an instrument purchased from Photon Technology 
International, Inc.; data from fluorometric studies were processed using Kaleidagraph. 
Gel imaging was achieved with a Bio-Rad ChemiDocTM XRS+ gel imager using 
ImgaeLabTM software. Protein yield was determined using a Shimadzu UV-1800 
spectrophotometer, using the sfGFP molar extinction coefficient of 83300 M-1cm-1.148 
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3.4.1. Organic Synthesis 
 
 
 
 
 
3-(Bromomethyl)benzaldehyde (6) 
Commercially available alpha-bromo m-toluinitrile 5 (5 g, 25.51 mmol) was 
dissolved in toluene and cooled to 0 ºC under an argon atmosphere. Diisobutylaluminum 
hydride (35.96 ml, 35.96 mmol, 1 M/Hexanes) was added dropwise to the solution, upon 
which the white opaque solution became clear and yellow. After 2 hrs, 66 ml of CHCl3 
was added to the solution, followed by 200 ml 10% HCl. After stirring for an additional 
hour, the organic layer was separated and washed with distilled water, then dried with 
Na2SO4 and concentrated to yield a clear oil, which crystallized overnight. The white 
crystals were filtered and washed with ice-cold hexanes, then allowed to dry to yield the 
desired compound in 94% yield (4.77 g). Spectroscopic data was in agreement with 
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literature values.162 1H NMR (300 MHz, CDCl3) δ 10.03 (s, 1H), 7.91 (s, 1H), 7.83 (d, J 
= 7.5 Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 4.55 (s, 2H). 13C NMR 
(75 MHz, CDCl3) δ 191.6, 138.9, 136.8, 134.9, 129.7, 32.1. 
Diethyl 2-Acetamido-2-(3-formylbenzyl)malonate (7) 
Alpha-bromo aldehyde 6 (4.52 g, 22.72 mmol), diethyl acetamidomalonate (4.44 
g, 20.45 mmol), K2CO3 (6.28 g, 45.44 mmol), and KI (3.77 g, 22.72 mmol) were 
suspended in 142 ml of anhydrous MeCN and heated to reflux. After 15 hrs, the reaction 
was cooled to room temperature, filtered, and concentrated. The resulting crude residue 
was dissolved in boiling hexanes with minimal amounts of ethyl acetate; a yellow solid 
was obtained upon cooling, which was washed with ice-cold hexanes and dried in vacuo 
to yield 7 in 72% yield (5.4 g). 1H NMR (300 MHz, CDCl3) δ 9.97 (s, 1H), 7.76 (d, J = 
7.5 Hz, 1H), 7.54 (s, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.29 (d, J = 7.5 Hz, 1H), 6.53 (s, 1H), 
4.28 (q, J = 6.9, 7.2 Hz, 4H), 4.12 (q, J = 7.2 Hz, 1H), 3.75 (s, 2H), 2.05 (s, 3H), 1.31 (t, 
J = 7.2 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 191.9, 169.3, 167.3, 136.5, 135.9, 130.3, 
129.2, 129.0, 67.0, 62.9, 37.4, 23.0, 14.0. 
2-Amino-3-(3-formylphenyl)propanoic Acid Hydrochloride (1) 
m-Formyl malonate 7 from the previous reaction (5 g, 14.91 mmol) was 
dissolved in 51.4 ml of 6 M HCl, and the resulting suspension was refluxed for 33 hrs. 
The resulting solution was cooled to room temperature and the solvent was removed in 
vacuo, then the solid product was filtered and washed with diethyl ether to remove any 
organic impurities. The resulting off-white solid was lyophilized overnight to yield the 
title compound in 90% yield (3.08 g). 1H NMR (300 MHz, D2O) δ 9.79 (s, 1H), 7.78 (dt, 
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J = 1.8, 6.9 Hz, 1H), 7.72 (s, 1H), 7.46-7.55 (m, 2H), 4.19 (t, J = 6.9 Hz, 1H), 3.25 (dd, J 
= 6.3, 14.7 Hz, 3H). 13C NMR (75 MHz, D2O) δ 195.9, 171.2, 136.1, 136.0, 135.1, 
130.3, 129.8, 129.7, 53.9, 35.2. 
 
 
 
 
 
tert-Butyl (2-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-
carboxamido)ethoxy)carbamate (9)  
To a solution of 5-carboxyfluorescein (0.10 g, 0.27 mmol), 4-
(dimethylamino)pyridine (10 mg, 0.08 mmol) and tert-butyl (2-
aminoethoxy)carbamate117 (53 mg, 0.30 mmol) in anhydrous DMF (2 mL) was added N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC hydrochloride, 78 
mg, 0.41 mmol), and the mixture was stirred at room temperature overnight. The mixture 
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was diluted in ethyl acetate (50 mL), washed with sodium hydroxide (0.5 M, 10 mL), 
hydrochloric acid (0.5 N, 10 mL) and brine (10 mL), dried (Na2SO4), evaporated, and 
chromatographed (EtOAc/hexanes, 1:3 to 1:1) to give 9 (0.10 g, 70%) as a yellow oil. 1H 
NMR (CD3OD, 500 MHz) δ 8.95 (t, 1 H, J = 5.5 Hz), 8.49 (s, 1 H), 8.24 (dd, 1 H, J = 
8.0, 1.5 Hz), 7.30 (d, 1 H, J = 8.0 Hz), 6.69 (d, 2 H, J = 2.0 Hz), 6.59 (d, 2 H, J = 9.0 
Hz), 6.53 (dd, 2 H, J = 9.0, 2.5 Hz), 3.99 (t, 2 H, J = 5.2 Hz), 3.67 (t, 2 H, J = 5.0 Hz), 
1.47 (s, 9 H); 13C NMR (CD3OD, 75 MHz) δ 170.7, 168.4, 161.5, 159.8, 156.9, 154.1, 
137.8, 135.7, 130.3, 128.8, 125.8, 125.0, 113.8, 111.0, 103.8, 82.7, 75.9, 39.9, 28.7; 
HRMS (ESI) calcd for C28H27N2O9 ([M+H]+) 535.1717, found 535.1234; calcd for 
C28H26N2O9Na ([M+Na]+) 557.1536, found 557.1028.  
N-(2-(Aminooxy)ethyl)-3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-
carboxamide Hydrochloride (4)  
To a solution of 9 (70 mg, 0.13 mmol) in 1,4-dioxane (1.0 mL) was added 
hydrogen chloride in dioxane (4.0 M, 0.3 mL, 1.2 mmol), and the mixture was stirred at 
room temperature for 4 h. The solvent was evaporated under high vacuum to afford 4 
(62 mg, quant.) as a yellow oil. 1H NMR (CD3OD, 500 MHz) δ 8.78 (s, 1 H), 8.35 (s, 1 
H), 7.57 (s, 1 H), 7.32 (bs, 2 H), 7.25 (bs, 2 H), 7.08 (bs, 2 H), 4.30 (bs, 2 H), 3.81 (bs, 2 
H); HRMS (ESI) calcd for C23H19N2O7 ([M+H]+) 435.1192, found 435.1292. 
3.4.2. Superfolder Green Fluorescent Protein (sfGFP) Expression 
sfGFPS2X Protein Sequence 
MAXKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKL
PVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTY
KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGI
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KANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKR
DHMVLLEFVTAAGITHGMDELYKGSHHHHHH 
X Denotes an amber stop codon where the non-canonical amino acid is incorporated. 
sfGFPN149X Protein Sequence 
MVSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKL
PVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTY
KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHXVYITADKQKNGI
KANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKR
DHMVLLEFVTAAGITHGMDELYKGSHHHHHH 
X Denotes an amber stop codon where the non-canonical amino acid is incorporated. 
sfGFPN149TAG Primers Sequences 
sfGFPN149TAG-F: 5’ - TAG GTG TAT ATT ACC GCC GAT AAA CAG AAA AAT 
GG - 3’ 
sfGFPN149TAG-R: 5’ - ATG GCT GTT GAA ATT ATA TTC CAG TTT ATG - 3’ 
Construction of pBAD-sfGFPN149TAG 
pBAD-sfGFP was a generous gift from Dr. Ryan Mehl at Franklin & Marshall 
College. sfGFP149TAG-F and sfGFP149TAG-R were used to perform the quick-change 
PCR on pBAD-sfGFP to afford pBAD-sfGFPN149TAG. This construct was 
cotransformed with pEVOL-PylT-PylRS-N346A/C348A into Top10 E. coli cells and 
used for sfGFP expression. 
Genetic Incorporation of m-Formyl Phenylalanine Into Superfolder GFP 
The procedure for expressing sfGFPS2TAG using BL21(DE3) E. coli has been 
reported previously.115,116 For expressing sfGFPN149TAG, Top10 E. coli cells 
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containing pBAD-sfGFPN149TAG and pEVOL-PylT-PylRS-N346A/C348A were used 
to inoculate 5 ml of LB media supplemented with Cm (34 µg/ml) and Amp (100 µg/ml), 
then grown overnight, followed by transfer to 500 ml of LB media containing Cm (34 
µg/ml) and Amp (100 µg/ml). When the cells had reached O.D.600 1.3-1.6, the culture 
was spun down for 20 min at 4,000 rpm, then the resulting pellet was resuspended with 
water and spun down once more. The pellet from this centrifugation was resuspended in 
15 ml ddH2O, and 5ml of this suspension was added to a flask containing 45 ml minimal 
media (33.7 mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 9.4 mM NH4Cl, 1 mM 
MgSO4, 0.3 mM CaCl2, 1% glycerol) supplemented with 2 mM non-canonical amino 
acid (NCAA). Induction occurred via addition of 0.2% arabinose and 1 mM IPTG. After 
12 hrs, the culture was centrifuged for 20 min at 4,000 rpm. The resulting pellet was 
resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8) and sonicated, then 
centrifuged for 1 hr at 4,000 rpm. The supernatant treated with imidazole to a final 
concentration of 10 mM, then incubated at 4 ºC for 1 h with Ni2+-NTA resin. The resin 
was washed with 10 mM imidazole (3 x column volume) and 20 mM imidazole (3 x 
column volume), and then eluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
500 mM imidazole, pH 8). The protein was dialyzed three times with 20 mM Tris buffer, 
pH 8.1, and concentrated using Amicon Ultra-cel 10k centrifugal filter units. Protein 
purity was determined via SDS-PAGE analysis and subjected to ESI-MS. 
Incorporation Using Autoinduction Media 
Proteins were expressed in a manner similar to the protocol described above, the 
exception being the use of autoinduction media developed by Mehl and co-workers.163 
  64 
The recipe used was identical to the referenced protocol except a different amino acid 
solution was utilized (400 µg/ml each of the following: glutamic acid sodium salt, 
aspartic acid, lysine hydrochloride, arginine hydrochloride, histidine hydrochloride 
monohydrate, alanine, proline, glycine, threonine, serine, glutamine, asparagine 
monohydrate, valine, leucine, isoleucine, tryptophan, and methionine). In other words, 
this 17 x amino acid solution differs from the reported recipe in that phenylalanine is 
removed to eliminate potential misincorporation. The cultures were allowed to grow 
overnight until a constant O.D. was obtained (1.82-1.83), upon which the cells were 
spun down, resuspended in lysis buffer, and sonicated. After centrifugation for 1 hr at 
4,000 rpm, the lysate was purified and analyzed as described above, yielding full-length 
sfGFP. 
 
 
 
Figure 3.5. ESI-MS data for sfGFPS2X-1, M9 minimal media. Predicted mass: 27756. 
Observed mass: 27757. 
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3.4.3. In Vitro Aniline-Catalyzed Labeling of sfGFP 
Determination of Second-Order Rate Constant 
A stock solution of sfGFP was added to a solution of 100 mM aniline and 100 
mM sodium phosphate, pH 7, to a total volume of 2 ml. To this solution was added 
coumarin-based dye 3, and the reaction rate was monitored with an excitation 
wavelength of 417nm and emission of 510 nm for 2 hours. This reaction was repeated 
with various concentrations of hydroxylamine dye while keeping the sfGFP 
concentration constant, and each resulting scatterplot was fitted to an exponential 
trendline. The observed rate constants obtained from these runs were plotted, and the 
second-order rate constant was derived as described in the manuscript. 
Time-Based Fluorescence Assay 
An aliquot of sfGFP-1 was diluted with a 2X stock of labeling buffer (200 mM 
aniline, 200 mM sodium phosphate, pH 7), with a final concentration of 8 µM sfGFP, 
100 mM aniline, and 100 mM sodium phosphate. To this was added 10 µM of 
fluorescein-based hydroxylamine dye. The reaction was quenched with 2 mM 
benzaldehyde and immediately treated with SDS-PAGE loading buffer, and the resulting 
samples were subjected to 12% SDS-PAGE analysis. Quenching occurred after 1, 5, 25, 
and 125 minutes to give the appropriate samples for the assay. The above procedure was 
also used for sfGFP-2. 
Fluorescence Assay Without Aniline Catalyst 
To a solution of sfGFP-1 in PBS buffer (8 µl, 3.6 µM) was added dye 4 (1.8 µl, 
20 µM) to a final concentration of 2.9 µM sfGFP and 3.6 µM dye 4. After the designated 
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amount of time had elapsed (1 h, 2 h, 7 h, and 18 h), the solution was precipitated using 
trichloroacetic acid, then the resulting pellet was washed twice with ice-cold acetone. 
After allowing the pellet to dry, it was resuspended in 20 µl H2O and prepared for SDS-
PAGE analysis using conventional methods. An identical procedure was performed for 
sfGFP-2, resulting in a total of eight reactions. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Bioconjugation of aldehyde in the absence of aniline catalyst at neutral pH. No 
appreciable labeling was observed with ketone-containing sfGFP-2. 
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3.4.4. In Vivo Labeling of OmpX 
OmpX Expression 
Expression of the membrane protein OmpX was performed as described 
previously.78 Briefly, BL21(DE3) cells cotransformed with pEVOL-pylT-
N346A/C348A and pETDuet-OmpXTAG were grown in 500 mL LB media until the 
O.D. reached 1.0-1.3, then the cells were pelleted and washed three times with PBS 
buffer. The cells were resuspended and transferred to 45 mL of minimal media 
supplemented with 2 mM NCAA, 1 mM IPTG, and 0.2% arabinose. Protein was 
expressed at 23 ºC for 10 h, and then the cells were pelleted and labeled as described 
below. 
In Vivo Labeling 
A 50 µL suspension of BL21(DE3) E. coli cells from procedure 4.1 was spun 
down for 5 min at 14,000 r.p.m., then resuspended in 100 µL labeling solution (100 mM 
aniline, 100 mM sodium phosphate, pH 7). Labeling was achieved by supplementing the 
suspension with 2 mM Dye 4, and the reaction was left at 23 ºC for 1 h. When complete, 
the cells were spun down for 5 min at 14,000 r.p.m., then resuspended in PBS buffer and 
centrifuged again. The previous step was repeated for a total of six PBS washes, and the 
pellet was resuspended once more in PBS buffer and visualized via confocal 
microscopy. 
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4. DEVELOPMENT OF CHEMICALLY MODIFIED PHAGE DISPLAY LIBRARIES  
4.1. Introduction 
Directed evolution is a powerful approach to discover useful mutants of a protein 
or peptide of interest, whereby extraordinarily large numbers of individuals can be 
screened simultaneously and selected against a property of interest.164 One of the 
requirements of a directed evolution study is that genotype and phenotype must be 
linked together. In other words, a given phenotype must be isolable and amplified using 
the specific genetic information that codes for such a phenotype. A prominent subset of 
directed evolution approaches include the “display” technologies, whereby a peptide or 
protein of interest is physically linked to the genetic information that codes for said 
peptide or protein. These various display systems have been developed for the in vitro 
selection of proteins, and each technique has its own method of linking phenotype to 
genotype. For example, techniques such as ribosome display and mRNA display rely on 
purified translational machinery to produce proteins; protein and mRNA are physically 
linked in an artificial manner. Conversely, other methodologies utilize entire 
microorganisms to link genotype and phenotype; these latter approaches include 
bacterial display, yeast display, and phage display. 
 Of the myriad techniques available for in vitro protein selection, phage display is 
among the most common approaches because its simplicity facilitates use by non-
specialists.165 George P. Smith initially reported phage display in 1985,166 wherein 
foreign peptides were expressed on the outer protein coat of filamentous phage. Since 
that initial report, phage display libraries are routinely utilized for evolving a variety of 
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antibodies, enzymes, and peptide-based inhibitors. Although peptide-based inhibitors are 
a useful class of compounds, the utilization of display technologies for their selection 
means these inhibitors are delegated to the twenty canonical amino acids, leaving them 
inherently limited from a chemical standpoint. Further, peptide-based inhibitors lack the 
stability and bioavailability that smaller molecules possess, which limits their medicinal 
applications. However, cyclization of peptides could circumvent these issues, and this 
task could be achieved via bioorthogonal reagents. The first attempts to expand chemical 
diversity in phage utilized bioconjugation techniques, notably with nucleophilic cysteine 
residues. However, installation of bioorthogonal reagents would negate chemoselectivity 
concerns when appending functionality to phage. Such bioorthogonal labeling would 
allow for functionalization with pharmacophores that may be inaccessible through 
straightforward genetic code expansion, such as β-lactones, epoxides, and aziridines. 
Schultz was the first to report successful genetic code expansion in phage 
systems using azidophenylalanine (AzF),167 verifying that non-canonical functionality 
could be directly incorporated into phage in a site-selective manner. Although this 
pioneering work demonstrates that a system such as phage display can tolerate 
expansion of the genetic code, the amber stop codon is delegated to a specific location at 
the N-terminal peptide. In order to take full advantage of an expanded genetic code in 
directed evolution experiments, it would be necessary to develop a means by which one 
could randomize the location of the amber stop codon. Development of a TAG-enriched 
phage display library is challenging, because phage harboring the amber codon will be 
reproduced at a lower rate than phage that are either wild type or lack in-frame amber 
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codons. Phage that possess in-frame amber codons will grow and propagate at a slower 
rate because of inherent inefficiencies of genetic code expansion, and translation with 
canonical incorporation machinery will be more facile than non-canonical amino acid 
incorporation. Over time, the number of phage containing in-frame amber codons will 
diminish and become a smaller representation of the overall population. Consequently, 
only a small percentage of phage with the desired modification would be present during 
selection, resulting in a low probability that selected mutants would have non-canonical 
amino acids. 
4.2. Progress Towards Developing a Non-Canonical Phage Display System 
 In order to address the above issues, our lab developed a method by which phage 
display libraries could be enriched in amber stop codons (Dr. Catrina Reed, unpublished 
results, Figure 4.1). The initial, naïve library was superinfected with CM13 phage, and 
pADLg3 plasmids capable of producing full-length P3 were immune to the 
superinfection. Phage susceptible to the superinfection (i.e. TAG-encoding or otherwise 
non-functional mutants) acquired the CM13 phagemid, and these individuals were 
selected via growth in the presence of Kan and Amp. The DNA from these surviving 
cells was isolated and used to transform DH5α cells harboring Μ13Κ07g3TAA, a helper 
phagemid with an in-frame ochre codon (TAA) to prevent competitive expression of 
wild type P3 protein. DH5α is an amber-suppressing strain, meaning it possesses 
translation machinery capable of reading through in-frame amber codons. Consequently, 
phage expression using this system led to library enrichment in amber codons, because 
individuals in the library that possessed other types of deleterious mutations were not 
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able to produce phage. Sequencing of the resulting library revealed that ten out of ten 
selected clones possessed an in-frame amber codon. 
 
 
 
 
  
 
 
The resulting TAG-enriched library, pADLg3-(NNK)7, was used to transform 
Top10 E. coli cells harboring two additional plasmids: pEVOL-(ClodF)-AzFRS and 
M13K07g3TAA. The pEVOL plasmid possesses a gene encoding azidophenylalanyl-
tRNA synthetase (AzFRS) and has a unique ClodF origin of replication to distinguish 
this plasmid from the competing origins in the other plasmids. M13K07g3TAA is a 
Superinfection
with CM13
Top10F'
pADLg3-NNK7
Grow on
Kan and Amp
pADLg3 has TAG
or deleterious
mutation
Immune to superinfection
due to P3 expression
Survivors have TAG
or deleterious mutation
in pADLg3
i.) Isolate pADLg3
ii.) Transform DH5α 
M13K07g3TAA
DH5α
M13K07g3TAA
pADLg3-NNK7
(TAG enriched)
i.) Phage amplification
ii.) Infect Top10F'
1.
2.
3.
4.
Figure 4.1. Strategy to acquire TAG-enriched phage libraries (Dr. Catrina Reed). Red 
plasmid: pADLg3-NNK7 library. Blue plasmid: CM13 phagemid. Purple plasmid: 
M13K07g3TAA helper phagemid. 
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helper phage, providing all components necessary for phage production, with the 
exception of the P3 protein (the g3 gene that encodes P3 has an in-frame TAA codon to 
prevent translation in this system); consequently, amplified phage must acquire P3 from 
the pADL plasmid, resulting in all viable phage to be within inclusion of the randomized 
(NNK)7 library. 
 Using this library, it was envisioned that phage could be functionalized with 
useful electrophilic moieties prior to selection. In order to demonstrate this technique, a 
β-lactone probe was synthesized; this lactone is derived from threonine, and was 
subsequently acylated by carboxylic acids possessing terminal alkynes.168,169 Threonine-
based lactones were chosen because they possess the ring strain (and reactivity) inherent 
to β-lactones, but are stable enough to tolerate labeling and panning conditions. 
Furthermore, this alkyne-functionalized β-lactone reacted sufficiently with azido-
coumarin, demonstrating its utility as a bioconjugation reagent (Figure 4.2). 
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With phage and probe in hand, it was then necessary to survey conditions that 
would permit bioconjugation while simultaneously maintaining the infectivity of phage. 
Since infectivity is crucial for amplification, potential binders may be lost simply 
because they could not be amplified after elution. Individually, each reagent had no 
impact on infectivity with respect to control experiments, but samples containing all 
reagents saw orders of magnitude less infectivity. However, through the use of copper-
chelating BTTAA, infectivity was maintained when treated under click chemistry 
conditions for one hour in PBS buffer. As a proof of principle, efforts are underway to 
select β-lactone based binders of tobacco etch virus (TEV) protease utilizing this 
approach (Figure 4.3); one round of selection has been attempted using a surface 
Figure 4.2. Copper-catalyzed azide-alkyne cycloaddition with β-lactone and 
azido-coumarin. Conditions: 2 mM β-lactone probe, 50 µM CuSO4, 300 µM 
BTTP, 2.5 mM sodium ascorbate, 5% DMSO, 100 mM potassium phosphate. 
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panning procedure, but no phages were detected in the elution by measuring the number 
of colony forming units (cfu). More optimization is needed with regards to the 
bioconjugation and panning procedures. 
 
 
 
 
 
 
4.3. Development of a Thiazolidine-Based Phage Display Library 
 The lack of chemical diversity is not the only limitation to phage display 
libraries. All inhibitors discovered via phage display would be peptide-based, and this 
class of compounds suffers from proteolytic susceptibility and poor cell permeability, 
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Figure 4.3. Strategy for functionalization and selection of phage possessing 
β-lactones. 
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both of which lower bioavailability.  Furthermore, selectivity is often an issue since 
peptides can achieve a number of conformations that allow them to interact with 
multiple targets. Peptide cyclization could potentially circumvent such issues,170-172 and 
methods to cyclize phage display libraries have been pursued in recent years.173,174 
 Among the approaches currently being studied, we hypothesized that aldehyde-
based linkages could be a useful means of constructing cyclic peptide libraries. In the 
presence of an N-terminal cysteine, aldehydes could spontaneously form thiazolidines, a 
stable heterocycle at neutral pH.175,176 In order to determine if this approach would be 
viable, a superfolder green fluorescent protein (sfGFP) fusion protein was constructed 
with a leader peptide possessing an N-terminal tobacco etch virus (TEV) recognition 
sequence, followed by cysteine, five consecutive alanines, and a genetically encoded 
aldehyde (3-formyl-phenylalanine, designated as “RCHO”). The resulting TEV-
Cys(Ala)5-RCHO-sfGFP protein was expressed, purified, and tested for cyclization 
(Figure 4.4). Upon cleavage of the TEV recognition site, the resulting N-terminal 
cysteine residue should be capable of condensing with 3-formyl phenylalanine to form 
the thiazolidine. In order to test this cyclization, the Cys(Ala)5-TAG-sfGFP protein was 
treated with a cyanobenzonitrile dye selective for N-terminal cysteines.177 If the N-
terminal cysteine does not react with aldehyde, it should be available for condensation 
with the cyanobenzonitrile dye. However, no such labeling was observed, and several 
controls were simultaneously assayed, including an attempt to label without TEV 
cleavage, and repetition of both experiments on the similar TEV-Cys(Ala)5Cys-sfGFP 
protein. Only one protein, Cys(Ala)5Cys-sfGFP, was successfully labeled. 
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The results discussed above were sufficient preliminary data to move forward 
with construction of a thiazolidine-based phage display library. Commercially available 
pADLg3 (Antibody Design Labs) containing full length P3 was subjected to PCR in 
order to install the necessary randomized sequence on the N-terminus of P3. Top10 E. 
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Figure 4.4. (A) General scheme for TEV cleavage and intramolecular cyclization. (B) SDS-PAGE 
analysis of proteins stained with Coomassie brilliant blue (top) and fluorescent imaging (bottom) 
demonstrating that only Cys(Ala)5Cys-sfGFP is labeled after TEV cleavage. Conditions: 8 µM 
GFP, 0.8 µM TEV protease, 50 mM sodium phosphate, 200 mM NaCl. C. Structure of FITC-CBT. 
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coli cells were transformed with the resulting pADLg3-Cys-(NNK)7-TAG plasmid, and 
the number of transformants was determined by plating 10-fold dilutions of the 
transformed cells onto agar plates containing ampicillin, and quantify the number of 
colony forming units (theoretical library size: 1.28 x 109, actual library size: 4.26 x 109). 
Currently, the constructed library has not been assessed for biases. However, given that 
the actual library size is greater than three times the theoretical size, it is likely that 
adequate representation of each possible individual has been obtained. 
4.4. Conclusion 
 The ability to obtain phage libraries enriched in amber codons has paved the way 
for developing a number of methodologies to expand the chemical diversity of phage. 
With TAG-enriched libraries in hand, one can perform directed evolution experiments 
wherein the non-canonical amino acid occurs in all possible locations within the peptide 
sequence, allowing for greater surveillance of the fitness landscape. Further, peptide 
cyclization via thiazolidine formation appears to be a plausible approach to obtain cyclic 
peptides, and work is underway to translate these preliminary protein trials to phage 
display systems. It is anticipated that the preliminary work reported herein will benefit 
those who wish to pursue methodologies involving chemically modified phage, a 
promising approach to discovering novel therapeutic peptides. 
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4.5. Detailed Experimental Protocols 
Organic synthesis was performed in oven-dried glassware under an argon 
atmosphere, and reagents were purchased and used without further purification. NMR 
spectra were obtained using Inova-300 and Mercury-300 instruments. All media was 
autoclaved and/or sterile filtered prior to use. Cloning and library construction utilized 
reagents and protocols obtained from New England Biolabs. For experiments involving 
phage, all pipettes and bench tops were washed thoroughly with 70% ethanol after use. 
Centrifugation was performed using a Sorvall Superspeed RC2-B automatic refrigerated 
centrifuge. Cell lysis was achieved with a VWR Scientific Branson Sonifier 450. 
Fluorometer data was obtained on an instrument purchased from Photon Technology 
International, Inc.; data from fluorometric studies were processed using Kaleidagraph. 
Gel imaging was achieved with a Bio-Rad ChemiDocTM XRS+ gel imager using 
ImgaeLabTM software. Protein yield was determined using a Shimadzu UV-1800 
spectrophotometer, using the sfGFP molar extinction coefficient of 83300 M-1cm-1. 
4.5.1. Organic Synthesis 
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N-((2R,3S)-2-Methyl-4-oxooxetan-3-yl)hex-5-ynamide 
Threonine-based β-lactone was synthesized according to an established literature 
procedure.178,179 To a suspension of this β-lactone (50 mg, 0.183 mmol) in 
dichloromethane (1.02 mL) was added triethylamine (0.1 mL, 0.732 mmol) dropwise, at 
which point the suspension became a clear solution. Hexynoyl chloride (35.78 mg, 0.274 
mmol) was added dropwise as a 1 M solution in dichloromethane at 0 ºC, and allowed to 
warm to room temperature overnight. After 16 h, the crude reaction mixture was 
concentrated in vacuo and immediately purified via silica gel chromatography (75% 
ethyl acetate/hexanes) to yield a white solid in 71% yield (25.2 mg). 1H NMR (300 
MHz, CDCl3) δ 6.46 (s, 1 H), 5.62 (m, 1 H), 4.90 (p, 1 H, J = 6.3 Hz), 2.43 (t, 2 H, J = 
7.5 Hz), 2.26 (m, 2 H), 2.00 (s, 1 H), 1.89 (p, 2 H, J = 7.2 Hz), 1.43 (d, 3 H, J = 6.3 Hz). 
13C NMR (75 MHz, CDCl3) δ 172.4, 169.4, 83.1, 75.0, 69.7, 58.9, 34.3, 23.8, 17.8, 15.1. 
4.5.2. pADLg3-(NNK)7 (TAG Enriched) 
pADLg3-(NNK)7 (TAG Enriched) Transformation 
To an ice-cold 0.6 mL tube was added 100 ng of pADLg3-Cys(NNK)7 (100 
ng/μL), and a suspension of electrocompetent Top10 cells (99 μL) harboring 
M13K07g3TAA and pEVOL-ClodF-AzFRS was slowly added by gently swirling the 
pipette while dispensing (100 μL total). From here, the suspension was transferred to a 
clean electroporator cuvette with a 2 mm gap. This procedure was repeated fifteen times. 
After each electroporation, cells were recovered by quickly adding 900 μL of pre-
warmed (37 ºC) 2YT, and this 1 mL culture was recovered for 1 h at 37 ºC. Then, the 
individual recovered cultures were pooled and grown in 500 mL of 2YT supplemented 
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with Kan (50 μg/mL), Amp (100 μg/mL), and Cm (34 μg/mL) overnight. Finally, cells 
were harvested by centrifugation for 20 min at 4,000 rpm, followed by resuspension in 
50 mL 20% glycerol/2YT supplemented with Kan (50 μg/mL), Amp (100 μL/mL), and 
Cm (34 μg/mL). Aliquots were stored at -80 ºC to be used later for phage expression. 
TAG-Enriched Phage Expression 
A 40 μL aliquot of E. coli Top10 cells containing helper phage M13K07g3TAA, 
synthetase plasmid pEVOL-(ClodF)-AzFRS, and pADLg3-Cys(NNK)7TAG library was 
used to inoculate 200 mL of 2YT media supplemented with Kan (50 μg/mL), Amp (100 μg/mL), and Cm (34 μg/mL). The initial optical density at 600 nm (O.D.600) was 0.04, 
and this culture was grown at 37 ºC until the O.D.600 equaled 0.56, then the culture was 
divided into two 100 mL samples (one as a control, another supplemented with AzF). P3 
and AzFRS expression was induced at 30 ºC for 12 h, with the addition of 0.2% 
arabinose, 0.5 mM IPTG, and 2 mM AzF. After 12 h, cells were centrifuged for 20 min 
at 4,000 rpm, and the supernatant was recovered. The phage were precipitated by 
addition of 20 mL of PEG precipitation solution (20% polyethylene glycol-8000, 2.5 M 
NaCl) and left overnight at 4 ºC. The next day, precipitated phage were recovered by 
centrifugation for 25 min at 11,000 x g, and the phage were resuspended in 5 mL 
phosphate buffered saline (PBS) by gently rocking at 4 ºC for 3 h. Residual E. coli were 
removed via centrifugation for 20 min at 4,000 rpm, the supernatant was transferred to a 
clean tube, and 2 mL PEG precipitation solution was added. After overnight 
precipitation at 4 ºC, phage were once again recovered by centrifugation for 25 min at 
11,000 x g, then resuspended in 1 mL PBS by gently pipetting. Residual E. coli were 
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removed via centrifugation for 20 min at 4,000 rpm, and the supernatant was transferred 
to a clean 1.5 mL Eppendorf tube. After heating to 65 ºC for 15 min, the purified phage 
were stored at 4 ºC until needed. The amount of phage present was determined by 
titering: phage were diluted 1,000-fold, used to infect Top10 F’ cells (O.D.600 = 0.4-0.6) 
for 45 min at 37 ºC, then these infected cells were diluted several orders of magnitude 
and grown on an Amp plate (100 μg/mL). 
Determining Reagent Effects on Infectivity 
100 μL of a CM13 phage suspension were diluted in 900 μL PBS containing 50 μM CuSO4, 50 μM sodium ascorbate, 50 μM β-lactone, and 300 μM BTTAA. After 
incubation for 1 h, 100 μL of this solution was used to infect Top10 F’ cells (O.D.600 = 
0.4-0.6) for 45 min, followed by serial dilution up to 10-8. 10 μL of each dilution was 
spotted onto an LB agar plate supplemented with Kan (50 μg/mL)	  and	  grown	  overnight	  at	  37	  ºC.	  As	  a	  control,	  a	  sample	  of	  CM13	  phage	  was	  also	  subjected	  to	  1	  h	  PBS	  only	  (no	  click	  reagents)	  and	  titered	  in	  the	  same	  manner.	  
4.5.3. Thiazolidine-based Peptide Cyclization and Library Construction 
sfGFP-Cys(Ala)5-TAG Primers 
CA5TAG Fwd: 
5’ – CGG CCG CGG CCT AGG TTA GCA AAG GTG AAG AAC TG – 3’ 
 
CA5TAG Rev: 
5’ – CGG CGC ACT GAA AAT ACA GGT TTT CCA TGG TTA ATT CCT CCT G – 
3’ 
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sfGFP-Cys(Ala)5-TAG Sequence 
DNA Sequence 
atggaaaacctgtattttcagtgcgccgcggccgcggcctaggttagcaaaggtgaagaactgtttaccggcgttgtgccgatt
ctggtggaactggatggtgatgtgaatggccataaatttagcgttcgtggcgaaggcgaaggtgatgcgaccaacggtaaact
gaccctgaaatttatttgcaccaccggtaaactgccggttccgtggccgaccctggtgaccaccctgacctatggcgttcagtgc
tttagccgctatccggatcatatgaaacgccatgatttctttaaaagcgcgatgccggaaggctatgtgcaggaacgtaccattag
cttcaaagatgatggcacctataaaacccgtgcggaagttaaatttgaaggcgataccctggtgaaccgcattgaactgaaagg
tattgattttaaagaagatggcaacattctgggtcataaactggaatataatttcaacagccataatgtgtatattaccgccgataaa
cagaaaaatggcatcaaagcgaactttaaaatccgtcacaacgtggaagatggtagcgtgcagctggcggatcattatcagca
gaataccccgattggtgatggcccggtgctgctgccggataatcattatctgagcacccagagcgttctgagcaaagatccgaa
tgaaaaacgtgatcatatggtgctgctggaatttgttaccgccgcgggcattacccacggtatggatgaactgtataaaggcagc
caccatcatcatcaccattaa 
Note: Amber stop codon highlighted in red. 
Peptide Sequence 
M E N L Y F Q C A A A A A X V S K G E E L F T G V V P I L V E L D G D V N G 
H K F S V R G E G E G D A T N G K L T L K F I C T T G K L P V P W P T L V T T 
L T Y G V Q C F S R Y P D H M K R H D F F K S A M P E G Y V Q E R T I S F K D 
D G T Y K T R A E V K F E G D T L V N R I E L K G I D F K E D G N I L G H K L E 
Y N F N S H N V Y I T A D K Q K N G I K A N F K I R H N V E D G S V Q L A D H 
Y Q Q N T P I G D G P V L L P D N H Y L S T Q S V L S K D P N E K R D H M V L 
L E F V T A A G I T H G M D E L Y K G S H H H H H H 
X denotes the location of a non-canonical amino acid.  
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sfGFP-Cys(Ala)5-TAG Cloning Procedure 
The above primers were used to perform a 50 μL scale PCR on pBAD-sfGFP-
Cys-Ala5-Cys with Phusion DNA polymerase. The amplified product was subjected to 
DpnI digestion for 2 h at 37 ºC, followed by ligation with T4 DNA ligase for 4 h at 23 
ºC. The ligated product was used to transform chemically competent Top10 cells, 
followed by growth on an Amp plate (100 μg/mL), and several colonies were selected 
for sequencing. The resulting plasmid was used with pEVOL-PylRS-N346A/C348A to 
co-transform chemically competent Top10 cells. After growth on an Amp/Cm plate, one 
colony was chosen to prepare cell stocks. 
Cys(Ala)5-RCHO-sfGFP Expression Procedure 
A 5 mL culture of E. coli Top10 cells containing pBAD-sfGFP-Cys-Ala5-TAG 
and pEVOL-PylRS-N346A/C348A were grown in Amp (100 μg/mL) and Cm (34 μg/mL) overnight, then used to inoculate 500 mL autoinduction media (the recipe used 
was identical to the referenced protocol except the amino acid solution utilized 400 
µg/ml each of the following: glutamic acid sodium salt, aspartic acid, lysine 
hydrochloride, arginine hydrochloride, histidine hydrochloride monohydrate, alanine, 
proline, glycine, threonine, serine, glutamine, asparagine monohydrate, valine, leucine, 
isoleucine, tryptophan, and methionine) with Amp (100 μg/mL) and Cm (34 μg/mL), 
supplemented with 2 mM 3-formyl phenylalanine. After the O.D.600 became constant 
(~5, 24 h) the cells were centrifuged for 20 min at 4,000 rpm, followed by sonication and 
subsequent centrifugation at 10,000 rpm for 1 h. The resulting sfGFP fusion protein was 
purified from the soluble fraction via nickel affinity chromatography (3x CV 10 mM 
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imidazole, 3x CV 20 mM imidazole), dialyzed against 10 mM ammonium bicarbonate 
(pH 8) and concentrated via speed vac to yield full-length protein (16 mg/L). 
 
 
 
 
 
 
 
 
 
Figure 4.5. ESI-MS data for full-length Cys(Ala)5-RCHO-sfGFP. Calculated mass: 29256 Da. 
Observed mass: 29298 Da (M + Acetyl). 
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N-Terminal Cysteine Labeling 
A sample of Cys(Ala)5-RCHO-sfGFP (100 μL, 8 μM) was incubated with TEV 
protease (final concentration: 0.8 μM) overnight (16 h) at 4 ºC. Then, a 20 μL aliquot 
was taken and treated with FITC-CBT for three hours. The reaction mixture was treated 
with 5 μL SDS-PAGE loading buffer, and the sample was boiled at 100 ºC for 10 min, 
then subjected to SDS-PAGE analysis. Prior to Coomassie staining, the gel was imaged 
to detect fluorescence from protein labeling. 
pADLg3-Cys(NNK)7-TAG Primers 
pADLg3-Cys(NNK)7-TAG Fwd: 
5’ – TAA CAT GGC ATG CNN KNN KNN KNN KNN KNN KNN KTA GGC GGC 
GAA AGC GGC – 3’ 
Figure 4.6. SDS-PAGE analysis of purified Cys(Ala)5-RCHO-sfGFP 
stained with Coomassie brilliant blue. Lane 1: no amino acid 
supplemented. Lane 2: 2 mM 3-formyl phenylalanine. 
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PelB-NcoI-Rev: 
5’-CATGCCATGGCCGGCTGGGCCGC-3’ 
pADLg3-Cys(NNK)7TAG Sequence 
DNA Sequence 
atgaaatacctattgcctacggcggccgctggattgttattactcgcggcccagccggccatggcatgcnnknnknnknnkn
nknnknnktaggcggcgaaagcggccggcccgggaggccaaggcggtggttctgagggtggtggctccctcgagggcg
cgccagccgaaactgttgaaagttgtttagcaaaacctcatacagaaaattcatttactaacgtctggaaagacgacaaaacttta
gatcgttacgctaactatgagggctgtctgtggaatgctacaggcgttgtggtttgtactggtgacgaaactcagtgttacggtac
atgggttcctattgggcttgctatccctgaaaatgagggtggtggctctgagggtggcggttctgagggtggcggttctgagggt
ggcggtactaaacctcctgagtacggtgatacacctattccgggctatacttatatcaaccctctcgacggcacttatccgcctgg
tactgagcaaaaccccgctaatcctaatccttctcttgaggagtctcagcctcttaatactttcatgtttcagaataataggttccgaa
ataggcagggtgcattaactgtttatacgggcactgttactcaaggcactgaccccgttaaaacttattaccagtacactcctgtat
catcaaaagccatgtatgacgcttactggaacggtaaattcagagactgcgctttccattctggctttaatgaggatccattcgtttg
tgaatatcaaggccaatcgtctgacctgcctcaacctcctgtcaatgctggcggcggctctggtggtggttctggtggcggctct
gagggtggcggctctgagggtggcggttctgagggtggcggctctgagggtggcggttccggtggcggctccggttccggt
gattttgattatgaaaaaatggcaaacgctaataagggggctatgaccgaaaatgccgatgaaaacgcgctacagtctgacgct
aaaggcaaacttgattctgtcgctactgattacggtgctgctatcgatggtttcattggtgacgtttccggccttgctaatggtaatg
gtgctactggtgattttgctggctctaattcccaaatggctcaagtcggtgacggtgataattcacctttaatgaataatttccgtcaa
tatttaccttctttgcctcagtcggttgaatgtcgcccttatgtctttggcgctggtaaaccatatgaattttctattgattgtgacaaaat
aaacttattccgtggtgtctttgcgtttcttttatatgttgccacctttatgtatgtattttcgacgtttgctaacatactgcgtaataagga
gtcttaa 
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“nnk” denotes a randomized codon (n = A, T, C, or G; k = G or T). The amber stop 
codon is highlighted in red. 
Peptide Sequence 
M K Y L L P T A A A G L L L L A A Q P A M A C J J J J J J J X A A K A A G P G G 
Q G G G S E G G G S L E G A P A E T V E S C L A K P H T E N S F T N V W K D D 
K T L D R Y A N Y E G C L W N A T G V V V C T G D E T Q C Y G T W V P I G L 
A I P E N E G G G S E G G G S E G G G S E G G G T K P P E Y G D T P I P G Y T Y 
I N P L D G T Y P P G T E Q N P A N P N P S L E E S Q P L N T F M F Q N N R F R 
N R Q G A L T V Y T G T V T Q G T D P V K T Y Y Q Y T P V S S K A M Y D A Y 
W N G K F R D C A F H S G F N E D P F V C E Y Q G Q S S D L P Q P P V N A G G 
G S G G G S G G G S E G G G S E G G G S E G G G S E G G G S G G G S G S G D F 
D Y E K M A N A N K G A M T E N A D E N A L Q S D A K G K L D S V A T D Y 
G A A I D G F I G D V S G L A N G N G A T G D F A G S N S Q M A Q V G D G D 
N S P L M N N F R Q Y L P S L P Q S V E C R P Y V F G A G K P Y E F S I D C D K 
I N L F R G V F A F L L Y V A T F M Y V F S T F A N I L R N K E S  
Where “J” denotes any of the twenty canonical amino acids, and X denotes a non-
canonical amino acid. 
pADLg3-Cys(NNK)7-TAG Library Construction 
Ten 50 μL scale PCR reactions were set up using Phusion DNA polymerase and 
the pADLg3-Cys(NNK)7-TAG primers mentioned above. After PCR, each reaction was 
subjected to DpnI digestion for 2 h at 37 ºC and purified via spin column. The purified 
product was then subjected to NcoI digestion for 22 h at 37 ºC, followed by gel 
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purification. From here, the purified, NcoI-digested DNA was subjected to T4 ligation 
for 16 h at 16 ºC. 
The ligated product from the above reaction was used to transform freshly 
prepared electrocompetent Top10 cells. To an ice-cold 0.6 mL tube was added 120 ng of 
pADLg3-Cys(NNK)7-TAG (27.4 ng/μL), and a suspension of Top10 cells was slowly 
added by gently swirling the pipette while dispensing (100 μL total). From here, the 
suspension was transferred to a clean electroporation cuvette with a 2 mm gap. This 
procedure was repeated seven times. After each electroporation, cells were recovered by 
quickly adding 900 μL of pre-warmed (37 ºC) 2YT, and this 1 mL culture was recovered 
for 1 h at 37 ºC. Then, the individual recovered cultures were pooled and grown in 500 
mL of 2YT supplemented with Amp (100 μL/mL) overnight. Finally, cells were 
harvested by centrifugation for 20 min at 4,000 rpm, followed by resuspension in 50 mL 
20% glycerol/2YT supplemented with Amp (100 μL/mL). 
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5. THE COPPER-CATALYZED AZIDE-ALKYNE CYCLOADDITION “CLICK” 
REACTION REQUIRES TWO DISTINCT MONONUCLEAR COPPER (I)-
CHELATING SPECIES  
5.1. Introduction 
The copper-catalyzed azide-alkyne cycloaddition (CuAAC) click reaction was 
first reported by Sharpless in 2002 and has been a boon to numerous fields, a fact 
underscored by thousands of citations the original reports have amassed.32,36,180 The 
widespread use of this reaction can be attributed to its chemoselectivity and reactivity 
under a variety of conditions, and it is robust enough to proceed in complex media such 
as biological systems. The advent of CuAAC has greatly facilitated endeavors such as 
the bioorthogonal labeling of biomacromolecules,39,181,182 the selective modification of 
carbon allotropes,35,38,183-185 and the rapid assembly of combinatorial libraries.37  
Despite numerous applications, the exact mechanism of CuAAC is still a 
contentious issue, though numerous mechanistic investigations have been reported186-192 
and a thorough review has recently been published.193 Early reports highlighted the 
importance of the copper acetylide intermediate, and the involvement of copper(I) 
species in the catalytic cycle.  The fact that the reaction is second-order with respect to 
copper(I) has led to postulation that two copper(I) atoms are involved in this process, 
either through dinuclear acetylide-based complexes or distinct chelation events for azide 
and alkyne. A recent report by Fokin191 has shown the need for a two-copper(I) process, 
and an ESI-MS study by De Angelis192 has reported direct observation of a dinuclear 
copper acetylide species. Most recently, a study by Bertrand194 utilized stable N-
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heterocyclic carbenes to isolate a dinuclear acetylide intermediate that was capable of 
undergoing CuAAC. Taken together, these publications remove some ambiguity 
regarding the nuclearity of CuAAC, and the most recent mechanistic proposal is shown 
in Figure 5.1.  
 
 
 
 
 
 
 
The reports mentioned above assert that a dinuclear copper acetylide is crucial 
for reactivity to occur, a species activated by both σ- and π-complexation of the alkyne 
starting material. According to this model, azide would subsequently interact with this 
dinuclear intermediate to undergo cycloaddition. However, isolation of an intermediate 
Figure 5.1. A proposed CuAAC mechanism by Fokin. Note the dinuclear copper 
intermediates in the bottom half of the mechanism. 
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does not necessarily mean that it is mechanistically relevant, as it is possible for said 
intermediate to undergo rearrangement or decomposition to intermediates that do have 
significant roles in catalysis. Further, there may be dynamic and unstable short-lived 
events that are crucial to successful completion of the catalytic cycle. One of these 
events, copper-azide chelation, has previously been postulated as an important step in 
the reaction mechanism,189,190 a possibility highlighted by several reports of CuAAC 
enhancement with copper-chelating azides.39,40,182,195 Although current models 
acknowledge azide-copper chelation, its exact role and placement in the reaction 
mechanism has not been unequivocally demonstrated in light of modern studies. Indeed, 
most recent reports have mainly focused on the nature of alkyne-copper interactions, 
with minimal scrutiny given to azide-copper interactions. 
Despite these advances in mechanistic understanding of CuAAC, some critical 
questions remain unanswered. How exactly are two coppers contributing to catalysis? Is 
dinuclear copper-alkyne binding a mechanistically relevant intermediate, or is it the 
product of a side reaction? In what manner does the azide interact with copper(I) and the 
alkyne? What exactly is the order of elementary chemical steps that lead to product 
formation? The dynamic nature of copper species in solution has made these questions 
challenging to answer, but we postulated that at least some of this information could be 
extracted via careful kinetic analysis. 
5.2. Results and Discussion  
 To probe the reaction mechanism of CuAAC, we utilized two non-fluorescent 
coumarin dyes that have been previously reported.40,196 The fluorogenic product 
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formation from CuAAC reactions of these two dyes allows for convenient monitoring of 
reaction trajectories via fluorescence. We initiated our investigations by using 
fluorescence-generating azido-coumarin 1 as the limiting reagent (Figure 5.2.A), and ran 
the reaction under pseudo-first order conditions with largely excess propargyl alcohol in 
100 mM potassium phosphate buffer. The other reagents such as CuSO4, the copper(I) 
ligand BTTAA, and the reducing reagent sodium ascorbate were kept constant, and the 
exact concentrations used were those reported in a paper detailing the optimization of 
CuAAC.34  
 
 
 
 
 
 
Figure 5.2. The model reactions used in this study. All reactions were carried out in 0.1 M 
potassium phosphate buffer, pH 7.4 with 5% DMSO. 
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Under these conditions, if there is an alkyne-copper(I) complex formation that is 
rate limiting or occurs prior to the rate-limiting step, then the reaction kinetics should 
show dependence based on alkyne concentration. The collected data of fluorescence 
intensity vs. time fit perfectly to the one phase exponential product formation model, 
allowing for readily determined observed reaction rate constants. However, there were 
no significant changes in observed rate constants over a number of different alkyne 
concentrations, indicating that the copper(I)-alkyne interaction, if there is any, and all 
other interactions involving alkyne occur after the rate-limiting step under the tested 
conditions (Figure 5.3). This observation was an unexpected result since it is in conflict 
with the model shown in Figure 1 and most of other popular models of CuAAC.191,192,194  
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We went to further probe the dependence of the reaction rate constant on the 
copper(I) concentration under conditions of largely excess propargyl alcohol. Using 
almost identical conditions as above with a fix concentration of propargyl alcohol at 1 
mM, but with variable copper concentrations, we observed a linear dependence of 
observed rate constant on copper(I) concentration (Figure 5.4). These results imply that 
only one stoichiometric equivalent of copper(I) is involved in the rate-determining step 
when alkyne is largely excessive, and that this process is much slower than steps 
involving alkyne. If any alkyne-involving step was rate limiting, or occurred prior to the 
A                           B   
Figure 5.3. CuAAC reactions of azido-coumarin in excessive propargyl alcohol. (A) 
The one phase exponential increase of the product fluorescence at different propargyl 
alcohol concentrations. Data were fit to the equation It = I0 + IC x 1 – e(-kobs x t) where I0 
is the background fluorescent intensity, It the fluorescent intensity at a specified time, Ic 
the fluorescent intensity change when azido-coumarin is fully changed to its 
corresponding fluorescent final product, and kobs the observed apparent rate constant. 
(B) Observed apparent rate constant kobs vs. propargyl alcohol concentration (the data 
were fit to a flat line). Conditions: 50 µM azido-coumarin, 0.25-4 mM propargyl 
alcohol, 2.5 mM sodium ascorbate, 300 µM BTTAA, 50 µM CuSO4. 
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rate-limiting step, there would also be observable alkyne dependence, though that is not 
the case.  
 
 
 
 
 
 
Based on the above data, a mechanism of CuAAC under these conditions is proposed 
in Figure 5.5. Under the conditions described above, the azide is the limiting reagent. Its 
one phase exponential decay, manifested by the one phase exponential increase of the 
product fluorescence, implies involvement of an azide-dependent process that must be 
A                           B   
Figure 5.4. CuAAC reactions of azido-coumarin in excessive propargyl alcohol but 
various copper concentrations. (A) The collected data of product fluorescence intensity vs. 
time at different copper concentrations. Data were fit to the equation It = I0 + IC x 1 – e(-
kobs x t) to obtain apparent observed rate constants at different conditions. (B) Observed 
apparent rate constant kobs vs. copper concentration (data were fit to a linear curve). 
Conditions: 50 µM azido-coumarin, 1 mM propargyl alcohol, 2.5 mM sodium ascorbate, 
300 + x µM BTTAA (x = [CuSO4]), 5-25 µM CuSO4. 
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rate limiting. Our data also demonstrates that interaction with one copper(I) atom is 
important for this slow process, presumably via chelation to azide. Subsequent steps 
must involve the alkyne, and two possibilities exist: 1) a single copper(I) atom recruits 
both azide and alkyne reagents, or 2) another copper(I) atom activates the alkyne for 
cycloaddition with azide. Given that most of studies pointed to two copper(I) atoms in 
the catalysis of CuAAC, the latter seems most likely. 
 
 
 
 
 
 
In order to probe the alkyne involvement processes in CuAAC, we employed 
limiting amounts of a non-fluorogenic alkyne-coumarin 4 with excess amounts of azide 
5. These conditions effectively speed up the azide-copper(I)chelation process as well as 
slow down the alkyne-dependent steps and therefore potentially ensure 
Figure 5.5. Limiting amounts of azide and excess amounts of alkyne lead 
to rate-limiting azide-copper(I) chelation. The observed apparent rate 
constant is determined by the equation kobs = k1 x [Cu+]. 
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that alkyne-based processes are rate limiting and observable. As before, conditions were 
based on the optimized concentrations reported previously,34 with micromolar amounts 
of 4 and millimolar amounts of 2-azidoethanamine. Under these conditions, the 
determined reaction rate constant shows linear dependence on azide concentration 
(Figure 5.6), indicating that the azide-copper(I) chelation occurs before further reaction 
with alkyne, a result that agrees well with observations using azido-coumarin 1. We also 
carried out the copper dependence study under conditions of largely excessive azide and 
limiting alkyne. The determined observed apparent rate constant vs. copper(I) 
concentration displayed a clearly second-order dependence (Figure 5.7), an observation 
A                               B   
Figure 5.6. CuAAC reactions of alkyne-coumarin in excessive 2-azidoethanamine. (A) The collected 
data of product fluorescence intensity vs. time at different 2-azidoethanamine concentrations. Data 
were fit to the equation It = I0 + IC x 1 – e(-kobs x t) to obtain observed apparent rate constants at 
different conditions. (B) Observed apparent rate constant kobs vs. 2-azidoethanamine concentration 
(data were fit to a linear curve). Conditions: 50 µM alkyne-coumarin, 0.5-8 mM 2-azidoethanamine, 
2.5 mM sodium ascorbate, 300 µM BTTAA, 50 µM CuSO4. 
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made by others and one that illustrates the importance of two distinct copper(I) atoms in 
the catalysis. 
 
 
 
 
 
 
Based on observations described above, we propose a CuAAC mechanism in 
conditions of largely excessive azide and limiting alkyne shown in Figure 5.8. Under 
these conditions, the excessive azide drives the fast formation of an azide-copper(I) 
complex that quickly reaches equilibrium with free azide and copper(I). This azide-
copper(I) complex then involves a relatively slow reaction with alkyne and a copper(I) 
A                                 B   
Figure 5.7. CuAAC reactions of alkyne-coumarin in excessive 2-azidoethanamine but various copper 
concentrations. (A) The collected data of product fluorescence intensity vs. time at different copper 
concentrations. Data were fit to the equation It = I0 + IC x 1 – e(-kobs x t) to obtain observed apparent 
rate constants at different conditions. (B) Observed apparent rate constant kobs vs. copper 
concentration (data were fit to a second-order model equation y = Ax2 + B). Conditions: 50 µM 
alkyne-coumarin, 10 mM 2-azidoethanamine, 2.5 mM sodium ascorbate, 300 + x µM BTTAA (x = 
[CuSO4]), 2.5-50 µM CuSO4. 
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atom to give the final cycloaddition product. Under this mechanism, the determined 
product formation displays a first-order dependence on the azide concentration and a 
second-order dependence on the copper(I) concentration. 
 
 
 
 
 
 
The kinetic data taken thus far have narrowed down the mechanism to two possible 
pathways shown in Figure 5.9. The pathway shown in blue involves a mononuclear 
transition state arrangement in which both azide and alkyne chelate to a single copper(I) 
atom. Subsequent interaction with a second copper(I) atom would somehow trigger 
formation of the final product, perhaps via π-complexation with alkyne; such an 
intermediate would be analogous to the most recent mechanistic proposal.191,192,194 The 
Figure 5.8. Limiting amounts of alkyne-coumarin 4 results in rate-
limiting processes involving alkyne. The observed apparent rate 
constant is determined by the equation kobs = k2 x [Cu+] x [R1-N3--Cu+] 
that can be further derived to be the equation kobs = [(k1 x k2)/k-1]x 
[Cu+]2 x [R1-N3]. When k1>>k-1, both free R1-N3 and Cu+ concentrations 
are essentially not varied due to their chelation.  
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second pathway (bottom, shown in red) involves two distinct copper(I) species, one 
chelated to azide and another interacting with alkyne, most likely as the sigma complex. 
Both copper(I)-chelating species would react together to form the triazole product. 
 
 
 
 
 
 
In order to distinguish between the two possibilities, a copper(I)-chelating azide 7 
was synthesized and is analogous to compounds reported recently.40 A number of reports 
Figure 5.9. Depiction of two mechanistic possibilities based on kinetic data shown above. 
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have been published describing the rapid rate enhancement of CuAAC when using 
copper-chelating azides,39,40 and we suspected that such a compound would facilitate 
kinetic investigations. By utilizing a copper(I)-chelating azide, rapid formation of a 
copper(I)-azide complex should occur, making other processes rate limiting. Using 
stopped-flow kinetics and a limiting amount of the chelating azide 7, a one-phase 
exponential product formation is expected if the mechanism in blue is correct (i.e. [R1-
N3]t = [R1-N3]0(1- e-kt)). However, under these conditions we observed a linear formation 
of product followed by a flat line that was not the typical, exponential curve for product 
formation (Figure 5.10.A). This data indicates that processes involving azide are not rate 
limiting, and that the rate of the product formation is determined by another slow step; 
based on process of elimination, this event must be copper(I)-alkyne complexation 
shown in red in Figure 5.9. Under the mechanism in red of Figure 5.9, where 7 is 
limiting and the copper(I)-alkyne complex formation is much slower than the following 
reaction  
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with the azide-copper(I) complex, the rate of consumption of 7 (or the rate of product 
formation) is determined by copper(I)-alkyne complexation with a constant rate defined 
by the equation v = k x [alkyne] x [Cu+] in which both concentrations of alkyne and 
copper(I) do not vary during reaction. We also tested reactions under conditions of 
limiting alkyne and excessive 7, and we once again observed the exponential increase in 
product formation (Figure 5.10.B). Under these conditions, the product formation 
manifested by the alkyne consumption follows a one-phase exponential increase model. 
Taken together, these experiments lead to rejection of the pathway shown in blue, and 
provide strong evidence to suggest the mechanism shown in red of Figure 5.9 is correct 
and the real cycloaddition reaction is much faster than the alkyne-copper(I) 
complexation. A revised mechanism is shown in Figure 5.11. In this mechanism, both 
alkyne and azide chelate copper(I) first and then react rapidly to form the final 
A                               B   
Figure 5.10. Stopped-flow kinetics of CuAAC between alkyne-coumarin 4 and a copper-chelating 
azide 7. (A) The product fluorescence intensity vs. time when 7 was limiting. Conditions: 20 µM 7, 200 
µM alkyne-coumarin, 20 µM CuSO4, 2.5 mM sodium ascorbate. (B) The product fluorescence intensity 
vs. time when 4 was limiting. Conditions: 20 µM alkyne-coumarin, 200 µM 7, 20 µM CuSO4, 2.5 mM 
sodium ascorbate. 
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cycloaddition product. The cycloaddition process is much faster than the two 
complexation steps, leading to all detected reaction rates in this study being related to 
copper(I)-azide and copper(I)-alkyne complexation. 
 
 
 
 
 
 
5.3. Concluding Remarks 
 The most recent mechanistic studies have shed light on the nuclearity of CuAAC, 
and the consensus currently points to formation of an acetylide intermediate activated 
via σ- and π-complexation. After formation of this dinuclear intermediate, azide 
chelation is postulated to occur, followed by cycloaddition. However, if this step 
occurred as hypothesized, our results would have differed in significant ways. For 
Figure 5.11. A refined mechanism based on the results of this study. 
 
Figure 11. A refined mechanism based on the results of this study. 
 
 
  104 
example, in situations where azido-coumarin is used in the presence of excess propargyl 
alcohol, we would have observed a second-order dependence on the copper(I) 
concentration that is typically seen for this reaction, in addition to linear dependence on 
the propargyl alcohol concentration. These hypothetical results would have supported 
rate-limiting formation of the dinuclear acetylide intermediate. The observation that the 
rate is independent of alkyne and first-order for copper leads to rejection of this order of 
events. Hypothetically, if azide chelation occurred after the rate-limiting step, we should 
observe zero order dependence on azide concentration. However, our observation that 
this reaction is first order with excess azide dismisses this idea. 
It is important to recognize that the successful isolation of an intermediate does not 
necessarily indicate this intermediate to be mechanistically relevant in a direct way. It is 
entirely possible that such an intermediate undergoes decomposition or rearrangement in 
solution to reveal intermediates that are actually involved in the mechanism. In the case 
for CuAAC, stable dinuclear acetylides have been isolated and utilized for triazole 
formation 194. Given the kinetic results in this paper, we propose that the π-bound copper 
from such an intermediate would have to dissociate from the acetylide to interact with 
azide, and the resulting complex would then undergo cycloaddition with copper 
acetylide. In other words, although the dinuclear copper acetylide can be isolated under 
certain conditions, it is most likely a non-productive intermediate that dissociates to 
generate mechanistically relevant species. Further, the successful isolation of this doubly 
activated alkyne required ligands that are electronically tuned to stabilize this 
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intermediate. Typically, copper-alkyne π-complexation is a weak interaction under 
standard conditions with conventional reagents. 
Prior to this work, there have been no reports that scrutinize the currently accepted 
mechanism with detailed kinetic analysis, which can elucidate the order of events in 
such a dynamic system. Given the results of our kinetic experiments, the proposed 
dinuclear copper acetylide does not occur prior to azide chelation events. Rather than 
delegating azide chelation to a later step in the catalytic cycle, we propose that it is a 
distinct chelation event that requires one atom of copper(I), and the other copper(I) atom 
activates the alkyne, most likely through an acetylide intermediate. After formation of 
both copper complexes, they come together to form the triazole product (Figure 5.11), 
possibly through π-interaction of the copper-azide complex with the σ-bound copper 
acetylide. Reports demonstrating the effectiveness of copper-chelating azides in CuAAC 
further emphasize the importance of azide chelation events in this reaction.  
We believe the results presented herein will help researchers develop new, more 
efficient catalysts for such a widely used reaction. Copper-chelating azides have been 
successful at enhancing the reaction rate of CuAAC, but these were designed with 
previous mechanistic models in mind. With our current understanding of copper-
catalyzed click chemistry, it may be possible to synthesize azides that further enhance 
the rate and efficiency of this venerable reaction. Through informed optimization of 
reagent and catalyst properties, it is expected that researchers will be successful in 
enhancing copper-catalyzed click chemistry even further than previously reported. 
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5.4. Detailed Experimental Protocols 
Unless otherwise noted, all reagents and solvents were used as purchased without 
further purification. All reactions were performed under an inert atmosphere, using 
oven-dried glassware and anhydrous solvents. Azido-coumarin 1, alkyne-coumarin 4, 
and BTTAA were synthesized based on published literature procedures.197-200 
An important caveat regarding CuAAC is that freshly prepared solutions of 
copper (ii) sulfate and sodium ascorbate are critical for success of the reaction, and 
efficacy of click chemistry diminishes with increased age of the stock solutions. 
Consequently, for the kinetic experiments described below, all measurements for a 
single plot were taken in a single day, using freshly prepared solutions of copper (ii) 
sulfate and sodium ascorbate. Enough stock solution was made for the anticipated 
number of reactions, in order to minimize experimental errors in preparing stock 
solutions that may lead to erroneous plot points. Data was collected using Felix GX 
software, and the raw data was transported to Kaleidagraph for data processing and 
curve fitting. For aesthetic reasons, the data shown in the main text was re-processed 
using Prism 6 software. The original data and curve fitting has been included in this 
document for the sake of transparency. 
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5.4.1. Organic Synthesis 
 
 
 
 
 
3-(Di(prop-2-yn-1-yl)amino)propan-1-ol (9) 
A previously reported procedure has been adapted.201 3-Amino-1-propanol (1.5g, 
20mmol) and K2CO3 (5.53g, 40mmol) was dissolved in 10 mL DCM and placed in an 
ice bath. Then, propargyl bromide (5.95g, 40mmol) in 3 mL DCM was added dropwise. 
After 3 hours, the reaction had reached completion, and the solvent was evaporated 
under reduced pressure. The crude material was directly subjected to column 
chromatography (DCM/EtOAc: 1/1) to afford 9 in 33% yield. 1H NMR (D2O, 300 
MHz): δ 3.63 (t, 2H, J=6.5Hz), 3.47 (s, 4H), 2.66 (t, 2H, J=7.5Hz), 1.73 (p, 2H, 
J=7.1Hz). 13C NMR (D2O, 75 MHz): δ 78.21, 74.69, 59.83, 49.39, 41.35, 28.89. 
2,2'-(((3-Hydroxypropyl)azanediyl)bis(1H-1,2,3-triazole-4,1-diyl))diacetic Acid(10) 
A previously reported procedure has been adapted.40 Compound 9 (317 mg, 
2.1mmol), ethyl 2-azido acetate (520mg, 4.2mmol, prepared according to a previously 
published report),202 and 5 mL tert butanol/water (1/1) were added to the reaction flask. 
Then, CuSO4.5H2O (52 mg, 0.21mmol) was added. Finally, the reaction flask was 
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placed in an ice bath, and sodium ascorbate (416 mg, 2.1mmol) was added in small 
portions over 2 minutes, then the ice bath was removed and the reaction was allowed to 
run overnight. After the reaction had reached to completion, solvent was evaporated 
under reduced pressure and the crude material was directly subjected to column 
chromatography (EtOAc/MeOH: 8/2) to afford 10 in 88% yield. 1H NMR (D2O, 300 
MHz): δ 8.02 (s, 2H), 5.37 (s, 4H), 4.25 (q, 4H, J=7.2Hz), 3.85 (s, 4H), 3.59 (t, 2H, 
J=6.3Hz), 2.59 (t, 2H, J=7.7Hz), 1.81 (p, 2H, , J=7.0Hz), 1.25 (t, 6H, J=7.7Hz). 13C 
NMR (D2O, 75 MHz): δ 168.58, 142.90, 126.61, 63.20, 60.05, 50.91, 49.60, 46.92, 
28.29, 13.15. 
2,2'-(((3-Azidopropyl)azanediyl)bis(1H-1,2,3-triazole-4,1-diyl))diacetic Acid (7) 
Compound 10 (190 mg, 0.5mmol), carbon tetrabromide (249mg, 0.75mmol) and 
2 mL anhydrous DMF were added to the reaction flask, and then the flask was placed in 
an ice bath. Triphenyl phosphine (197 mg, 0.75mmol) was added and mixture was 
stirred for 30 minutes on ice under inert atmosphere. After the allotted time had passed, 
one drop of water was added to the reaction mixture. Following this, NaN3 (195mg, 
3mmol) was added, then the ice bath was removed and the reaction was stirred 
overnight. After the reaction had reached completion, solvent was evaporated under 
reduced pressure and the crude material was directly subjected to column 
chromatography (EtOAc) to afford 7 in 49% yield. 1H NMR (D2O, 300 MHz): δ 8.01 (s, 
2H), 5.37 (s, 4H), 4.27 (q, 4H, J=7.2Hz), 3.86 (s, 4H), 3.31 (t, 2H, J=6.5Hz), 2.56 (t, 2H, 
J=7.3Hz), 1.82 (p, 2H, J=7.1Hz), 1.26 (t, 6H, J=7.1Hz). 13C NMR (CD3OD, 75 MHz): δ 
168.58, 145.75, 127.02, 63.32, 51.91, 51.30, 50.51, 27.73, 14.53 
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ESI Mass Analysis (m/z): Calculated: 435.2217; Found: 435.2225 
5.4.2. General Procedure for Pseudo-First Order Reactions 
Azido-Coumarin 
Table 5.1.  Reagent table for pseudo-first order CuAAC with azido-coumarin. 
 
 
 
Copper (ii) sulfate was added to an empty cuvette, followed by addition of 
BTTAA. The resulting solution was mixed well, followed by DMSO, potassium 
phosphate buffer, and water (in that order). Azido-coumarin was then added to the 
solution, followed by sodium ascorbate, and the resulting reaction mixture was placed in 
the fluorometer. Data acquisition was initiated for fifteen seconds, then acquisition was 
Reagent [Stock] [Rxn]
CuSO4
BTTAA
DMSO
KH2PO4
Azido-coumarin
Propargyl alcohol
Sodium ascorbate
25 mM
20 mM
100%
0.4 M
20 mM
1 M
25 mM
50 µM
300 µM
5%
0.1 M
50 µM
1 mM
2.5 mM
4 µL
Vol. (2000 µL total)
100 µL
30 µL
500 µL
5 µL
2 µL
200 µL
H2O 1159 µLN/A N/A
  110 
paused, propargyl alcohol was added, and data acquisition was resumed. When altering 
the concentration of one reagent, care was taken to ensure the volume was identical in all 
cases (2000 µL) in order to minimize error, a precaution easily done by increasing or 
decreasing the volume of water necessary. For trials labeled “adjusted BTTAA”, the 
actual BTTAA concentration was (300 + x) μM, where x = [CuSO4]. 
 
 
 
 
 
 
Figure 5.12. Reaction progress curves for azido-coumarin with excess propargyl alcohol. 
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Figure 5.13. Reaction rate dependence on propargyl alcohol concentration. 
Figure 5.14. Reaction progress curves for azido-coumarin with excess propargyl alcohol and 
variable copper sulfate concentration. 
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Figure 5.15. Reaction rate dependence on copper sulfate concentration. 
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Alkyne-Coumarin 
Table 5.2. Reagent table for pseudo-first order CuAAC with alkyne-coumarin. 
 
 
 
The procedure for alkyne-coumarin was identical to the one described above, 
except alkyne-coumarin and 2-azidoethanamine was added instead of azido-coumarin 
and propargyl alcohol, respectively. Again, caution was taken to ensure that the reaction 
volume was identical in all cases. For trials labeled “adjusted BTTAA”, the 
concentration of BTTAA was equal to (300 + x) μM, where “x” is equal to the 
concentration of copper sulfate.  
 
Reagent [Stock] [Rxn]
CuSO4
BTTAA
DMSO
KH2PO4
Alkynyl-coumarin
2-azidoethanamine
Sodium ascorbate
25 mM
20 mM
100%
0.4 M
20 mM
1 M
25 mM
50 µM
300 µM
5%
0.1 M
50 µM
1 mM
2.5 mM
4 µL
Vol. (2000 µL total)
100 µL
30 µL
500 µL
5 µL
2 µL
200 µL
H2O 1159 µLN/A N/A
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Figure 5.16. Reaction progress curves for alkyne-coumarin with excess 2-azidoethanamine. 
Figure 5.17. Reaction rate dependence on 2-azidoethanamine concentration. 
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Figure 5.18. Reaction progress curves for alkyne-coumarin with excess 2-azidoethanamine and 
variable copper sulfate concentration. 
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5.4.3. General Procedure for Stopped-Flow Kinetics 
To assess the kinetic parameters of the copper-chelating azide, two separate 1 mL 
solutions were prepared. To prepare solution A, reagents were added to a clean 1.5 mL 
Eppendorf tube in the following order: copper (ii) sulfate, azide 7, DMSO, potassium 
phosphate buffer, water, and sodium ascorbate. Solution B was a 1 mL solution of 
alkyne-coumarin in water, prepared in a separate 1.5 mL Eppendorf tube. Both solutions 
were independently taken up using two 1 mL syringes and simultaneously injected into 
the stopped flow apparatus. Data acquisition was triggered to occur at the moment 
injection was complete. 
Figure 5.19. Reaction rate dependence on copper sulfate concentration. 
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Excess Azide 
Table 5.3. Reagent table for stopped flow kinetics with excess azide 7. 
 
 
Reagent [Stock] [Rxn]
CuSO4
DMSO
KH2PO4
Alkyne-coumarin
Azide 7
Sodium ascorbate
25 mM
100%
0.4 M
20 mM
20 mM
25 mM
50 µM
5%
0.1 M
20 µM
2.5 mM
4 µL
100 µL
500 µL
2 µL
20 µL
200 µL
H2O 176 µLN/A N/A
200 µM
998 µL
Soln. A (1000 µL) Soln. B (1000 µL)
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Figure 5.20. Product formation curve for excessive azide 7 and limiting amounts 
of alkyne-coumarin. 
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Excess Alkyne 
Table 5.4. Reagent table for stopped flow kinetics with excess alkyne-coumarin. 
 
 
 
 
 
 
 
Reagent [Stock] [Rxn]
CuSO4
DMSO
KH2PO4
Alkyne-coumarin
Azide 7
Sodium ascorbate
25 mM
100%
0.4 M
20 mM
20 mM
25 mM
50 µM
5%
0.1 M
200 µM
2.5 mM
4 µL
100 µL
500 µL
20 µL
2 µL
200 µL
H2O 194 µLN/A N/A
20 µM
980 µL
Soln. A (1000 µL) Soln. B (1000 µL)
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Figure 5.21. Product formation curve for limiting azide 7 and excessive amounts 
of alkyne-coumarin. 
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6. SUMMARY  
 The results presented herein have demonstrated the utility of non-canonical 
phenylalanine derivatives in chemical biology for probing biological systems. Using an 
expanded genetic code of long-chain, meta-substituted phenylalanine derivatives, the 
steric tolerances of PylRS (N346A/C348) were explored, and its ability to incorporate all 
of the long-chain substrates is a testament to its superb promiscuity, a desirable trait 
because a variety of amino acids can be installed with a single system, minimizing the 
need for evolving novel mutants for each substrate. This information has been utilized to 
synthesize sterically similar amino acids for incorporation with PylRS(N346A/C348).  
Moreover, it has been demonstrated that PylRS (N346A/C348A) can successfully 
incorporate 3-formyl-phenylalanine, an aldehyde-containing amino acid that is highly 
reactive at physiological pH, yet is robust enough to survive protein expression 
conditions.  This marks the first time that aldehydes could be directly incorporated using 
amber suppression methodology; previous efforts utilized indirect methods of chemical 
or enzymatic post-translational modifications, and these approaches were further limited 
to the modification of protein termini or in-frame loop regions. In addition to its utility 
as a labeling handle, 3-formyl-phenylalanine has also been a useful approach to obtain 
cyclic peptides, via thiazolidine linkages that are stable in neutral pH. It is expected that 
the rich chemistry of aldehydes will result in the utilization of 3-formyl-phenylalanine 
for a number of different research efforts, some of which will be pursued in the Liu 
laboratory. Of the potential projects involving 3-formyl-phenylalanine, the most pressing 
endeavor is the successful selection of thiazolidine-based cyclic peptide inhibitors using 
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phage display technology, which could greatly facilitate drug discovery efforts upon 
optimization of the methodology. Finally, phenylalanine derivatives have played an 
indirect role in discovering key features of an important bioorthogonal reaction. In an 
attempt to optimize bioconjugation with azidophenylalanine in a phage display context, 
it was discovered that currently accepted models of CuAAC do not account for all 
kinetic data presented in this Dissertation. Based on this data, it is now proposed that 
CuAAC requires two distinct copper(I)-chelating events, with one stoichiometric 
equivalent of copper(I) chelating to azide, and another equivalent interacting with 
alkyne.  Cycloaddition occurs after both copper-chelating events occur. It is expected 
that the kinetic data presented in Chapter V will be useful to researchers who wish to 
develop copper-chelating reagents with optimized properties to further enhance such an 
important bioorthogonal reaction. To conclude, the work presented in this Dissertation 
has expanded the techniques available to researchers who require such methodologies 
for the isolation, modification, and manipulation of chemically interesting proteins.    
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APPENDIX B 
NMR AND MS DATA FOR SECTION 3 
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APPENDIX C 
NMR DATA FOR SECTION 4 
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APPENDIX D 
NMR DATA FOR SECTION 5 
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